

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
 IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
 USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUIDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
 INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
 added to TULSA
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
 visualization results
NEWS 16 FEB 22 Status of current WO (PCT) information on STN
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 21 FEB 28 TOXCENTER reloaded with enhancements
NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
 property data
NEWS 23 MAR 01 INSPEC reloaded and enhanced

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
 V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 22:19:33 ON 02 MAR 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL
 ENTRY SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 22:19:40 ON 02 MAR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9
 DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e topiramate/cn

```
E1      1      TOPILOTAMIDE/CN
E2      1      TOPIOSOMERASE I/CN
E3      1 --> TOPIRAMATE/CN
E4      1      TOPIRAMID/CN
E5      1      TOPISOLON/CN
E6      1      TOPITRACIN/CN
E7      1      TOPITRIOL/CN
E8      1      TOPIXANTRONE/CN
E9      1      TOPKOL C 330/CN
E10     1      TOPKOL LM/CN
E11     1      TOPKOL S/CN
E12     1      TOPLAMID 1011/CN
```

=> s s3


```
L1      1      TOPIRAMATE/CN
```

=> d

```
L1      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN      97240-79-4  REGISTRY
```

ED Entered STN: 21 Jul 1985
 CN β -D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, β -D-fructopyranose deriv.
 OTHER NAMES:
 CN 2,3:4,5-Bis-O-(1-methylethylidene) β -D-fructopyranose sulfamate
 CN Epitomax
 CN McN 4853
 CN RWJ 17021
 CN Topamax
 CN **Topiramate**
 CN Topomax
 FS STEREOSEARCH
 MF C12 H21 N O8 S
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
 DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,
 MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE,
 TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

795 REFERENCES IN FILE CA (1907 TO DATE)
 15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 803 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file merck

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

7.10	7.31
------	------

FILE 'MRCK' ENTERED AT 22:20:14 ON 02 MAR 2006

COPYRIGHT (C) 2006 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Right

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005

THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.


=> s 3.1

L2 1 L1

=> d

L2 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2006 Merck and Co., Inc.,
 Whitehouse Station, New Jersey, USA. All rights reserved. on STN
 MERCK Number (MNO): 9625
 CAS Registry No. (RN): 97240-79-4
 MERCK Index Name (MIN): Topiramate
 Molecular Form. (MF): C12 H21 N O8 S
 Wgt Composition (COMP): C 42.47%, H 6.24%, N 4.13%, O 37.72%, S 9.45%.
 Molecular Weight (MW): 339.36

Absolute stereochemistry. Rotation (-).



=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.87

9.18

FILE 'MEDLINE' ENTERED AT 22:20:41 ON 02 MAR 2006

FILE LAST UPDATED: 2 MAR 2006 (20060302/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s {anticonvulsant?}

L3 3 (ANTICONVULSANT?)

=> s anticonvulsant?

L4 32693 ANTICONVULSANT?

=> s anticonvuls?

L5 33208 ANTICONVULS?

=> s l4 or l5

L6 33208 L4 OR L5

=> s topiramate

L7 1300 TOPIRAMATE

=> s (cancer or tumor?)

530906 CANCER

782672 TUMOR?

L8 1134070 (CANCER OR TUMOR?)

=> s l6 and l8

L9 598 L6 AND L8

=> s l7 and l8

L10 10 L7 AND L8

=> d 1-10

L10 ANSWER 1 OF 10 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2005286456 MEDLINE

DN PubMed ID: 15846125

TI Clinical activity of venlafaxine and **topiramate** against oxaliplatin-induced disabling permanent neuropathy.

AU Durand Jean-Philippe; Alexandre Jerome; Guillevin Loic; Goldwasser Francois

CS Unite d'oncologie medicale, Service de medecine interne, Groupe Hospitalier Cochin, GHU Ouest, Assistance Publique-Hopitaux de Paris, Universite Paris V, France.

SO Anti-cancer drugs, (2005 Jun) Vol. 16, No. 5, pp. 587-91. Journal code: 9100823. ISSN: 0959-4973.

CY England: United Kingdom

DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200509

ED Entered STN: 20050604

Last Updated on STN: 20050920

Entered Medline: 20050919

L10 ANSWER 2 OF 10 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2005180802 MEDLINE

DN PubMed ID: 15813358

TI [Etiology and treatment of epilepsy in the elderly].
Etiologija i liječenje epilepsije osoba starije dobi.

AU Miskov Snjezana; Roje Bedekovic Marina; Mikula Ivan; Demarin Vida

CS Klinika za neurologiju, Klinicka bolnica Sestre milosrdnice, Zagreb, Hrvatska.. snjezana.miskov@zg.hinet.hr

SO Acta medica Croatica : c asopis Hrvatske akademije medicinskih znanosti, (2005) Vol. 59, No. 1, pp. 63-7.

Journal code: 9208249. ISSN: 1330-0164.

CY Croatia
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Croatian
 FS Priority Journals
 EM 200505
 ED Entered STN: 20050408
 Last Updated on STN: 20050504
 Entered Medline: 20050503

L10 ANSWER 3 OF 10 MEDLINE on STN

Full Text	References
--------------	------------

AN 2005105765 MEDLINE
 DN PubMed ID: 15686894
 TI Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?.
 AU Vullo Daniela; Innocenti Alessio; Nishimori Isao; Pastorek Jaromir; Scozzafava Andrea; Pastorekova Silvia; Supuran Claudiu T
 CS Universita degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy.
 SO Bioorganic & medicinal chemistry letters, (2005 Feb 15) Vol. 15, No. 4, pp. 963-9.
 Journal code: 9107377. ISSN: 0960-894X.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200506
 ED Entered STN: 20050302
 Last Updated on STN: 20050616
 Entered Medline: 20050615

L10 ANSWER 4 OF 10 MEDLINE on STN

Full Text	References
--------------	------------

AN 2005002183 MEDLINE
 DN PubMed ID: 15478125
 TI Sulfamates and their therapeutic potential.
 AU Winum Jean-Yves; Scozzafava Andrea; Montero Jean-Louis; Supuran Claudiu T
 CS Laboratoire de Chimie Biomoléculaire, Université Montpellier II, UMR 5032, Ecole Nationale Supérieure de Chimie de Montpellier, 8 rue de l'Ecole Normale, 34296 Montpellier Cedex, France.. winumj@univ-montp2.fr
 SO Medicinal research reviews, (2005 Mar) Vol. 25, No. 2, pp. 186-228. Ref: 143
 Journal code: 8103150. ISSN: 0198-6325.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200506
 ED Entered STN: 20050104
 Last Updated on STN: 20050604
 Entered Medline: 20050603

L10 ANSWER 5 OF 10 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2004313785 MEDLINE
 DN PubMed ID: 15215649
 TI Inhibition of alpha(1E) Ca(2+) channels by carbonic anhydrase inhibitors.
 AU McNaughton Nicolle C L; Davies Ceri H; Randall Andrew
 CS Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK.
 SO Journal of pharmacological sciences, (2004 Jun) Vol. 95, No. 2, pp. 240-7.
 Journal code: 101167001. ISSN: 1347-8613.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200501
 ED Entered STN: 20040625
 Last Updated on STN: 20050106
 Entered Medline: 20050105

L10 ANSWER 6 OF 10 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2004006995 MEDLINE
 DN PubMed ID: 14704123
 TI Inhibitory effect of **topiramate** on Lewis lung carcinoma metastasis and its relation with AQP1 water channel.
 AU Ma Bing; Xiang Yang; Li Tao; Yu He-Ming; Li Xue-Jun
 CS Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing 100083, China.
 SO Acta pharmacologica Sinica, (2004 Jan) Vol. 25, No. 1, pp. 54-60.
 Journal code: 100956087. ISSN: 1671-4083.
 CY China
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200408
 ED Entered STN: 20040106
 Last Updated on STN: 20040821
 Entered Medline: 20040820

L10 ANSWER 7 OF 10 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2003601463 MEDLINE
 DN PubMed ID: 14684331
 TI Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, **tumor**-associated isozyme IX.
 AU Abbate Francesco; Casini Angela; Owa Takashi; Scozzafava Andrea; Supuran Claudiu T
 CS Universita degli Studi di Firenze, Polo Scientifico, Dipartimento di Chimica, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, Rm. 188, I-50019 Sesto Fiorentino, Florence, Italy.
 SO Bioorganic & medicinal chemistry letters, (2004 Jan 5) Vol. 14, No. 1, pp. 217-23.
 Journal code: 9107377. ISSN: 0960-894X.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200408

ED Entered STN: 20031220
 Last Updated on STN: 20040828
 Entered Medline: 20040827

L10 ANSWER 8 OF 10 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2003584332 MEDLINE
 DN PubMed ID: 14665823
 TI Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate.
 AU Sokolski Kenneth N; Denson Thomas F
 CS VA Long Beach Healthcare System, Mental Health Care Group, Long Beach, California 90822, USA.. kenneth.sokolski@med.va.gov
 SO Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, (2003 Dec) Vol. 16, No. 4, pp. 234-8. Journal code: 101167278. ISSN: 1543-3633.
 CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200402
 ED Entered STN: 20031216
 Last Updated on STN: 20040302
 Entered Medline: 20040227

L10 ANSWER 9 OF 10 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2003390187 MEDLINE
 DN PubMed ID: 12927809
 TI Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes.
 AU Gustafson Birgit; Jack Maia M; Cushman Samuel W; Smith Ulf
 CS Department of Internal Medicine, The Lundberg Laboratory for Diabetes Research, The Sahlgrenska Academy at Goteborg University, Goteborg SE-413 45, Sweden.
 SO Biochemical and biophysical research communications, (2003 Sep 5) Vol. 308, No. 4, pp. 933-9. Journal code: 0372516. ISSN: 0006-291X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200310
 ED Entered STN: 20030821
 Last Updated on STN: 20031015
 Entered Medline: 20031014

L10 ANSWER 10 OF 10 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001447964 MEDLINE
 DN PubMed ID: 11303740
 TI **Topiramate** promotes neurite outgrowth and recovery of function after nerve injury.
 AU Smith-Swintosky V L; Zhao B; Shank R P; Plata-Salaman C R
 CS CNS Research, Drug Discovery, The R.W. Johnson Pharmaceutical Research

Institute, Spring House, PA 19477-0776, USA.
 SO Neuroreport, (2001 Apr 17) Vol. 12, No. 5, pp. 1031-4.
 Journal code: 9100935. ISSN: 0959-4965.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 20010813
 Last Updated on STN: 20010813
 Entered Medline: 20010809

=> d kwic 6

L10 ANSWER 6 OF 10 MEDLINE on STN

Using References

TI Inhibitory effect of **topiramate** on Lewis lung carcinoma metastasis and its relation with AQP1 water channel.
 AB AIM: To study the effect of **topiramate** on **tumor** metastasis and its relation with aquaporin 1 (AQP1) water channel. METHODS: Lewis lung carcinoma metastatic model was used to determine the effect of **topiramate** on **tumor** growth and metastasis. Colorimetric estimation was used to investigate the action of **topiramate** on carbonic anhydrase (CA) activity. Western blotting and immunohistochemical analysis were used to study the influence of **topiramate** on AQP1 water channel expression in lungs or **tumor** tissues of mice bearing Lewis lung carcinoma. RESULTS: Treatment with **topiramate** (120 mg/kg/d, ig for 20 d) reduced the growth of primary **tumor** significantly (P<0.05). Its inhibitory rate of metastasis was 81.25 %. **Topiramate** inhibited CA activity in lungs of mice in a dose-dependent manner. **Topiramate** apparently decreased AQP1 protein expression and immunostaining in lungs or in **tumor** microvessel endothelial cells of mice. CONCLUSION: Suppression of AQP1 water channel expression may be an important pathway for the inhibitory effect of **topiramate** on **tumor** metastasis.
 RN 146410-94-8 (Aquaporin 1); 30237-26-4 (Fructose); 97240-79-4 (**topiramate**)

=> s fructopyranose sulfamate

52 FRUCTOPYRANOSE

252 SULFAMATE

L11 11 FRUCTOPYRANOSE SULFAMATE
 (FRUCTOPYRANOSE (W) SULFAMATE)

=> d his

(FILE 'HOME' ENTERED AT 22:19:33 ON 02 MAR 2006)

FILE 'REGISTRY' ENTERED AT 22:19:40 ON 02 MAR 2006

E TOPIRAMATE/CN

L1 1 S E3

FILE 'MRCK' ENTERED AT 22:20:14 ON 02 MAR 2006

L2 1 S L1

FILE 'MEDLINE' ENTERED AT 22:20:41 ON 02 MAR 2006

L3 3 S (ANTICONVULANT?)

L4 32693 S ANTICONVULSANT?

L5 33208 S ANTICONVULS?

L6 33208 S L4 OR L5
 L7 1300 S TOPIRAMATE
 L8 1134070 S (CANCER OR TUMOR?)
 L9 598 S L6 AND L8
 L10 10 S L7 AND L8
 L11 11 S FRUCTOPYRANOSE SULFAMATE

=> s l8 and l11

L12 0 L8 AND L11

=> s fructopyranose?

L13 52 FRUCTOPYRANOSE?

=> s l8 and l13

L14 1 L8 AND L13

=> d

L14 ANSWER 1 OF 1 MEDLINE on STN

Full Text Citing
 References

AN 2005356474 MEDLINE
 DN PubMed ID: 16010362
 TI Synthesis, cytotoxicity, cellular uptake and influence on eicosanoid metabolism of cobalt-alkyne modified fructoses in comparison to auranofin and the cytotoxic COX inhibitor Co-ASS.
 AU Ott Ingo; Koch Thao; Shorafa Hashem; Bai Zhenlin; Poeckel Daniel; Steinhilber Dieter; Gust Ronald
 CS Institute of Pharmacy, Free University of Berlin, Konigin-Luise-Str. 2 + 4, 14195 Berlin, Germany.
 SO Organic & biomolecular chemistry, (2005 Jun 21) Vol. 3, No. 12, pp. 2282-6. Electronic Publication: 2005-05-25.
 Journal code: 101154995. ISSN: 1477-0520.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200511
 ED Entered STN: 20050713
 Last Updated on STN: 20051103
 Entered Medline: 20051101

=> file uspatall

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.60	15.78

FILE 'USPATFULL' ENTERED AT 22:28:09 ON 02 MAR 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 22:28:09 ON 02 MAR 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s anticonvulsant?

L15 7379 ANTICONVULSANT?

=> s anticonvuls?

L16 7977 ANTICONVULS?

```
=> s topiramate
L17      994 TOPIRAMATE

=> s {cancer or tumor?}
L18      157015 (CANCER OR TUMOR?)

=> s fructopyranose sulfamate
L19      99 FRUCTOPYRANOSE SULFAMATE

=> s l15 or l16
L20      7977 L15 OR L16

=> s l18 and l20
L21      2842 L18 AND L20

=> s l17 and l18
L22      629 L17 AND L18

=> s l19 and l19
L23      17 L18 AND L19

=> s anticonvulsant?/clm
L24      649 ANTICONVULSANT?/CLM

=> s anticonvuls?/clm
L25      727 ANTICONVULS?/CLM

=> s topiramate/clm
L26      266 TOPIRAMATE/CLM

=> s {cancer or tumor?}/clm
L27      34083 (CANCER OR TUMOR?)/CLM

=> s fructopyranose sulfamate/clm
L28      13 FRUCTOPYRANOSE SULFAMATE/CLM

=> s l24 or l25
L29      727 L24 OR L25

=> s l27 and l29
L30      75 L27 AND L29

=> s l26 and l27
L31      66 L26 AND L27

=> s l27 and l28
L32      0 L27 AND L28

=> d l31 1-66
```

L31 ANSWER 1 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN	2006:10664	USPATFULL
TI	Constrained cyano compounds	
IN	Campbell, David Alan, San Diego, CA, UNITED STATES	
	Betancort, Juan Manuel, San Diego, CA, UNITED STATES	
	Winn, David T., San Diego, CA, UNITED STATES	
<u>PI</u>	<u>US 2006009518</u>	A1 20060112
<u>AI</u>	<u>US 2005-179797</u>	A1 20050712 (11)

PRAI US 2004-587391P 20040712 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2992
 INCL INCLM: 514/522.000
 INCLS: 558/410.000
 NCL NCLM: 514/522.000
 NCLS: 558/410.000
 IC IPCI A61K0031-277 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 2 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN	2005:331228	USPATFULL
TI	Combination therapy for the treatment of obesity	
IN	MacNeil, Douglas J., Westfield, NJ, UNITED STATES McIntyre, James H., Piscataway, NJ, UNITED STATES Van Der Ploeg, Leonardus H. T., Scotch Plains, NJ, UNITED STATES Ishihara, Akane, Tsukuba, Ibaraki, JAPAN	
PI	US 2005288213	A1 20051229
AI	US 2003-520566	A1 20030714 (10)
	WO 2003-US22077	20030714
		20050107 PCT 371 date
PRAI	US 2003-396603P	20020718 (60)
	US 2003-417999P	20021011 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	3064	
INCL	INCLM: 514/002.000 INCLS: 514/278.000; 514/454.000; 514/635.000; 514/369.000	
NCL	NCLM: 514/002.000 NCLS: 514/278.000; 514/369.000; 514/454.000; 514/635.000	
IC	[7] ICM A61K038-17 ICS A61K031-4747; A61K031-353; A61K031-155 IPCI A61K0038-17 [ICM,7]; A61K0031-4747 [ICS,7]; A61K0031-353 [ICS,7]; A61K0031-155 [ICS,7]	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L31 ANSWER 3 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN	2005:318097	USPATFULL
TI	Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents	
IN	Wilson, Michelle, Hamilton, OH, UNITED STATES Desai, Kishorkumar J., Westchester, OH, UNITED STATES Pauletti, Giovanni M., Loveland, OH, UNITED STATES Antoon, Mitchell K. JR., Cincinnati, OH, UNITED STATES Clendening, Chris E., Cleves, OH, UNITED STATES	
PI	US 2005276836	A1 20051215
AI	US 2005-180076	A1 20050712 (11)
RLI	Continuation-in-part of Ser. No. <u>US 2005-126863</u> , filed on 10 May 2005, PENDING Continuation-in-part of Ser. No. <u>US 2002-226667</u> , filed on 21 Aug 2002, PENDING Continuation-in-part of Ser. No. <u>US 2003-600849</u> , filed on 20 Jun 2003, PENDING Continuation-in-part of Ser. No. <u>US 2003-349029</u> , filed on 22 Jan 2003, GRANTED, Pat. No. <u>US 6905701</u> Continuation-in-part of Ser. No. <u>US 2000-626025</u> , filed on 27 Jul 2000, GRANTED, Pat. No. <u>US 6572874</u> Continuation-in-part of Ser. No. <u>US 1999-249963</u> , filed on 12 Feb	

1999, GRANTED, Pat. No. US 6086909 Continuation-in-part of Ser. No. US 1998-79897, filed on 15 May 1998, GRANTED, Pat. No. US 6197327

PRAI US 2004-587454P 20040712 (60)
US 1997-49325P 19970611 (60)

DT Utility

FS APPLICATION

LN.CNT 2549

INCL INCLM: 424/422.000

NCL NCLM: 424/422.000

IC [7]

ICM A61F013-00

IPCI A61F0013-00 [ICM,7]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 4 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:255711 USPATFULL

TI Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease

IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES

Manning, Donald C., Bloomsbury, NJ, UNITED STATES

Faleck, Herbert, West Orange, NJ, UNITED STATES

PI US 2005222209 A1 20051006

AI US 2005-93848 A1 20050330 (11)

PRAI US 2004-559261P 20040401 (60)

DT Utility

FS APPLICATION

LN.CNT 1715

INCL INCLM: 514/323.000

NCL NCLM: 514/323.000

IC [7]

ICM A61K031-454

IPCI A61K0031-454 [ICM,7]

IPCR A61K0031-4523 [I,C]; A61K0031-454 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 5 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:215591 USPATFULL

TI Sulfonylpyrrolidine modulators of androgen receptor function and method

IN Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES

Bi, Yingzhi, Plainsboro, NJ, UNITED STATES

Manfredi, Mark C., Hamilton, NJ, UNITED STATES

Nirschl, Alexandra A., Yardley, PA, UNITED STATES

Sutton, James C., Princeton Junction, NJ, UNITED STATES

PI US 2005187267 A1 20050825

AI US 2005-48439 A1 20050201 (11)

PRAI US 2004-541869P 20040204 (60)

DT Utility

FS APPLICATION

LN.CNT 2593

INCL INCLM: 514/362.000

INCLS: 514/423.000; 548/537.000; 548/126.000

NCL NCLM: 514/362.000

NCLS: 514/423.000; 548/126.000; 548/537.000

IC [7]

ICM A61K031-433

ICS A61K031-4015; C07D498-04

IPCI A61K0031-433 [ICM,7]; A61K0031-4015 [ICS,7]; C07D0498-04 [ICS,7]
 IPCR A61K0031-4015 [I,A]; A61K0031-4015 [I,C]; A61K0031-433 [I,A];
 A61K0031-433 [I,C]; C07D0498-00 [I,C]; C07D0498-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 6 OF 66 USPATFULL on STN

Full Text	Citing References
AN	2005:215566 USPATFULL
TI	Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
IN	Weinstein, David S., East Windsor, NJ, UNITED STATES Gilmore, John L., Yardley, PA, UNITED STATES Sheppeck, James, Newtown, NJ, UNITED STATES Yang, Bingwei Vera, Belle Mead, NJ, UNITED STATES Kim, Soong-Hoon, Titusville, NJ, UNITED STATES Vaccaro, Wayne, Yardley, PA, UNITED STATES
PI	US 2005187242 A1 20050825
AI	US 2005-35176 A1 20050113 (11)
PRAI	US 2004-537469P 20040116 (60)
DT	Utility
FS	APPLICATION
LN.CNT	3546
INCL	INCLM: 514/295.000 INCLS: 546/097.000; 514/235.200; 514/256.000
NCL	NCLM: 514/295.000 NCLS: 514/235.200; 514/256.000; 546/097.000
IC	[7] ICM A61K031-473 ICS C07D417-02; C07D413-02 IPCI A61K0031-473 [ICM,7]; C07D0417-02 [ICS,7]; C07D0413-02 [ICS,7] IPCR A61K0031-473 [I,A]; A61K0031-473 [I,C]; C07D0413-00 [I,C]; C07D0413-02 [I,A]; C07D0417-00 [I,C]; C07D0417-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 7 OF 66 USPATFULL on STN

Full Text	Citing References
AN	2005:209625 USPATFULL
TI	Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof
IN	Yang, Bingwei Vera, Belle Mead, NJ, UNITED STATES
PI	US 2005182110 A1 20050818
AI	US 2005-35119 A1 20050113 (11)
PRAI	US 2004-537470P 20040116 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2148
INCL	INCLM: 514/370.000 INCLS: 514/374.000; 548/190.000; 548/233.000
NCL	NCLM: 514/370.000 NCLS: 514/374.000; 548/190.000; 548/233.000
IC	[7] ICM A61K031-426 ICS A61K031-421 IPCI A61K0031-426 [ICM,7]; A61K0031-421 [ICS,7] IPCR A61K0031-421 [I,A]; A61K0031-421 [I,C]; A61K0031-426 [I,A]; A61K0031-426 [I,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 8 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:209620 USPATFULL

TI Method of using 3-cyano-4-arylpuridine derivatives as modulators of androgen receptor function

IN Nirschl, Alexandra A., Yardley, PA, UNITED STATES
Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES

PI US 2005182105 A1 20050818

AI US 2005-48437 A1 20050201 (11)

PRAI US 2004-541780P 20040204 (60)

DT Utility

FS APPLICATION

LN.CNT 1913

INCL INCLM: 514/340.000
INCLS: 514/344.000

NCL NCLM: 514/340.000
NCLS: 514/344.000

IC [7]
ICM A61K031-4439
ICS A61K031-44
IPCI A61K0031-4439 [ICM,7]; A61K0031-44 [ICS,7]
IPCR A61K0031-44 [I,A]; A61K0031-44 [I,C]; A61K0031-4427 [I,C];
A61K0031-4439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 9 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:209598 USPATFULL

TI Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof

IN Weinstein, David S., East Windsor, NJ, UNITED STATES
Sheppeck, James, Newtown, PA, UNITED STATES
Gilmore, John L., Yardley, PA, UNITED STATES

PI US 2005182083 A1 20050818

AI US 2005-35290 A1 20050113 (11)

PRAI US 2004-537048P 20040116 (60)

DT Utility

FS APPLICATION

LN.CNT 2881

INCL INCLM: 514/286.000
INCLS: 546/063.000

NCL NCLM: 514/286.000
NCLS: 546/063.000

IC [7]
ICM C07D487-04
ICS A61K031-4745
IPCI C07D0487-04 [ICM,7]; A61K0031-4745 [ICS,7]
IPCR A61K0031-4738 [I,C]; A61K0031-4745 [I,A]; C07D0403-00 [I,C];
C07D0403-12 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 10 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:209597 USPATFULL

TI Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof

IN Duan, Jingwu, Yardley, PA, UNITED STATES

Sheppeck, James, Newtown, PA, UNITED STATES
 Jiang, Bin, Norristown, PA, UNITED STATES
 Gilmore, John L., Yardley, PA, UNITED STATES

PI US 2005182082 A1 20050818
AI US 2005-34822 A1 20050113 (11)
PRAI US 2004-537437P 20040116 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2376
 INCL INCLM: 514/284.000
 INCLS: 546/074.000
 NCL NCLM: 514/284.000
 NCLS: 546/074.000
 IC [7]
 ICM A61K031-473
 ICS C07D221-28
 IPCI A61K0031-473 [ICM,7]; C07D0221-28 [ICS,7]
 IPCR A61K0031-439 [I,A]; A61K0031-439 [I,C]; A61K0031-473 [I,A];
 A61K0031-473 [I,C]; A61K0031-4748 [I,A]; A61K0031-4748 [I,C];
 C07D0221-00 [I,C]; C07D0221-28 [I,A]; C07D0401-00 [I,C];
 C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0417-00 [I,C];
 C07D0417-12 [I,A]; C07D0471-00 [I,C]; C07D0471-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 11 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:209565 USPATFULL
 TI Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists
 IN Howard, Harry Ralph JR., Bristol, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
PI US 2005182049 A1 20050818
AI US 2005-46974 A1 20050131 (11)
PRAI US 2004-540517P 20040129 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1692
 INCL INCLM: 514/227.500
 NCL NCLM: 514/227.500
 IC [7]
 ICM A61K031-541
 IPCI A61K0031-541 [ICM,7]
 IPCR A61K0031-541 [I,A]; A61K0031-541 [I,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 12 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:203324 USPATFULL
 TI Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
 IN Yang, Bingwei Vera, Belle Mead, NJ, UNITED STATES
PI US 2005176749 A1 20050811
AI US 2005-34635 A1 20050113 (11)
PRAI US 2004-537468P 20040116 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1934
 INCL INCLM: 514/285.000

INCLS: 514/370.000; 546/062.000; 548/190.000
 NCL NCLM: 514/285.000
 NCLS: 514/370.000; 546/062.000; 548/190.000
 IC [7]
 ICM A61K031-4745
 ICS A61K031-426; C07D471-02
 IPCI A61K0031-4745 [ICM,7]; A61K0031-426 [ICS,7]; C07D0471-02 [ICS,7]
 IPCR A61K0031-426 [I,A]; A61K0031-426 [I,C]; A61K0031-4738 [I,C];
 A61K0031-4745 [I,A]; C07D0471-00 [I,C]; C07D0471-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 13 OF 66 USPATFULL on STN

Full Text	References
--------------	------------

AN 2005:203291 USPATFULL
 TI Modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof
 IN Duan, Jingwu, Yardley, PA, UNITED STATES
 Jiang, Bin, Norristown, PA, UNITED STATES
 Sheppeck, James, Newtown, PA, UNITED STATES
 Gilmore, John L., Yardley, PA, UNITED STATES
 PI US 2005176716 A1 20050811
 AI US 2005-34652 A1 20050113 (11)
 PRAI US 2004-537467P 20040116 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2100
 INCL INCLM: 514/249.000
 INCLS: 544/343.000
 NCL NCLM: 514/249.000
 NCLS: 544/343.000
 IC [7]
 ICM A61K031-498
 ICS C07D417-02; C07D043-02; C07D241-36
 IPCI A61K0031-498 [ICM,7]; C07D0417-02 [ICS,7]; C07D0043-02 [ICS,7];
 C07D0241-36 [ICS,7]
 IPCR A01N0043-48 [I,C]; A01N0043-58 [I,A]; A01N0043-60 [I,A];
 A61K0031-495 [I,A]; A61K0031-495 [I,C]; A61K0031-498 [I,A];
 A61K0031-498 [I,C]; A61K0031-50 [I,A]; A61K0031-50 [I,C];
 C07D0241-00 [I,C]; C07D0241-36 [I,A]; C07D0417-00 [I,C];
 C07D0417-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 14 OF 66 USPATFULL on STN

Full Text	References
--------------	------------

AN 2005:196997 USPATFULL
 TI HMG-CoA reductase inhibitors and method
 IN O'Connor, Stephen P., Lambertville, NJ, UNITED STATES
 Robl, Jeffrey, Newtown, PA, UNITED STATES
 Ahmad, Saleem, Wall, NJ, UNITED STATES
 Bisaha, Sharon, Lambertville, NJ, UNITED STATES
 Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES
 Ngu, Khehyong, Pennington, NJ, UNITED STATES
 Shi, Yan, Flourtown, PA, UNITED STATES
 Stein, Philip D., Pennington, NJ, UNITED STATES
 Soundararajan, Nachimuthu, Kendall Park, NJ, UNITED STATES
 Natalie, Kenneth J. JR., Flemington, NJ, UNITED STATES
 Kolla, Laxma R., Plainsboro, NJ, UNITED STATES
 Sausker, Justin, Middletown, CT, UNITED STATES

Quinlan, Sandra L., West Simsbury, CT, UNITED STATES
 Fan, Junying, Monmouth Junction, NJ, UNITED STATES
 Petsch, Dejah, Ashford, CT, UNITED STATES
 Guo, Zhenrong, East Brunswick, NJ, UNITED STATES

PI US 2005171140 A1 20050804
 AI US 2004-989138 A1 20041115 (10)
 PRAI US 2003-523546P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4392
 INCL INCLM: 514/300.000
 INCLS: 546/122.000
 NCL NCLM: 514/300.000
 NCLS: 546/122.000
 IC [7]
 ICM A61K031-4745
 ICS C07D471-02
 IPCI A61K0031-4745 [ICM,7]; C07D0471-02 [ICS,7]
 IPCR A61K0031-435 [I,A]; A61K0031-435 [I,C]; A61K0031-4738 [I,C];
 A61K0031-4745 [I,A]; A61K0031-505 [I,A]; A61K0031-505 [I,C];
 C07D0401-00 [I,C]; C07D0401-14 [I,A]; C07D0471-00 [I,C];
 C07D0471-02 [I,A]; C07D0471-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 15 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2005:196967 USPATFULL
 TI Azabicyclic heterocycles as cannabinoid receptor modulators
 IN Yu, Guixue, Princeton Junction, NJ, UNITED STATES
 Ewing, William R., Yardley, PA, UNITED STATES
 Mikkilineni, Amarendra B., Easton, PA, UNITED STATES
 Pendri, Annapurna, Glastonbury, CT, UNITED STATES
 Ellsworth, Bruce A., Princeton, NJ, UNITED STATES
 Sher, Philip M., Plainsboro, NJ, UNITED STATES
 Gerritz, Samuel, Guilford, CT, UNITED STATES
 Sun, Chongqing, East Windsor, NJ, UNITED STATES
 Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES
 Wu, Ximao, Princeton Junction, NJ, UNITED STATES
 PI US 2005171110 A1 20050804
 AI US 2004-16198 A1 20041217 (11)
 PRAI US 2003-531451P 20031219 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2556
 INCL INCLM: 514/248.000
 INCLS: 544/236.000
 NCL NCLM: 514/248.000
 NCLS: 544/236.000
 IC [7]
 ICM A61K031-503
 ICS C07D487-04
 IPCI A61K0031-503 [ICM,7]; C07D0487-04 [ICS,7]
 IPCR A61K0031-5025 [I,A]; A61K0031-5025 [I,C]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 16 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2005:176825 USPATFULL
 TI Method of biochemical treatment of persistent pain
 IN Omoigui, Osemwota Sota, Tarzana, CA, UNITED STATES
 PI US 2005152905 A1 20050714
 AI US 2005-58371 A1 20050216 (11)
 RLI Continuation-in-part of Ser. No. US 2002-224743, filed on 22 Aug 2002,
 PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 4032
 INCL INCLM: 424/145.100
 INCLS: 514/012.000; 514/102.000; 514/089.000; 514/154.000; 514/263.310;
 514/171.000; 424/239.100; 514/569.000; 514/570.000; 514/420.000;
 514/406.000; 514/217.000; 514/023.000; 514/561.000; 514/557.000;
 514/355.000; 514/301.000; 514/282.000
 NCL NCLM: 424/145.100
 NCLS: 424/239.100; 514/012.000; 514/023.000; 514/089.000; 514/102.000;
 514/154.000; 514/171.000; 514/217.000; 514/263.310; 514/282.000;
 514/301.000; 514/355.000; 514/406.000; 514/420.000; 514/557.000;
 514/561.000; 514/569.000; 514/570.000
 IC [7]
 ICM A61K039-395
 ICS A61K031-675; A61K031-66; A61K031-573
 IPCI A61K0039-395 [ICM,7]; A61K0031-675 [ICS,7]; A61K0031-66 [ICS,7];
 A61K0031-573 [ICS,7]
 IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C]; A61K0038-17 [I,A];
 A61K0038-17 [I,C]; A61K0038-43 [I,C]; A61K0038-48 [I,A];
 C07K0016-18 [I,C]; C07K0016-24 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 17 OF 66 USPATFULL on STN

Full Text	Long References
--------------	--------------------

AN 2005:165956 USPATFULL
 TI Azabicyclic heterocycles as cannabinoid receptor modulators
 IN Yu, Guixue, Princeton Junction, NJ, UNITED STATES
 Ewing, William R., Yardley, PA, UNITED STATES
 Mikkilineni, Amarendra B., Easton, PA, UNITED STATES
 Pendri, Annapurna, Glastonbury, CT, UNITED STATES
 Sher, Philip M., Plainsboro, NJ, UNITED STATES
 Gerritz, Samuel, Guilford, CT, UNITED STATES
 Ellsworth, Bruce A., Princeton, NJ, UNITED STATES
 Wu, Gang, Princeton, NJ, UNITED STATES
 Huang, Yanting, Pennington, NJ, UNITED STATES
 Sun, Chongqing, East Windsor, NJ, UNITED STATES
 Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES
 Gu, Zhengxiang, Princeton, NJ, UNITED STATES
 Wang, Ying, Princeton, NJ, UNITED STATES
 Sitkoff, Doree, Dresher, PA, UNITED STATES
 Johnson, Stephen R., Erdenheim, PA, UNITED STATES
 Wu, Ximao, Princeton Junction, NJ, UNITED STATES
 PI US 2005143381 A1 20050630
 AI US 2004-16135 A1 20041217 (11)
 PRAI US 2003-531451P 20031219 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5350
 INCL INCLM: 514/248.000
 INCLS: 544/236.000
 NCL NCLM: 514/248.000

NCLS: 544/236.000
 IC [7]
 ICM A61K031-503
 ICS C07D487-04
 IPCI A61K0031-503 [ICM,7]; C07D0487-04 [ICS,7]
 IPCR A61K0031-5025 [I,A]; A61K0031-5025 [I,C]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 18 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:144921 USPATFULL
 TI Substituted azole acid derivatives useful as antidiabetic and
 antiobesity agents and method
 IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES
 Hariharan, Narayanan, Richboro, PA, UNITED STATES
 PI US 2005124661 A1 20050609
 AI US 2004-12810 A1 20041215 (11)
 RLI Division of Ser. No. US 2002-294525, filed on 14 Nov 2002, PENDING
 Continuation-in-part of Ser. No. US 2002-153454, filed on 22 May 2002,
 ABANDONED
 PRAI US 2001-294380P 20010530 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3878
 INCL INCLM: 514/332.000
 INCLS: 514/340.000; 546/256.000; 546/268.100
 NCL NCLM: 514/332.000
 NCLS: 514/340.000; 546/256.000; 546/268.100
 IC [7]
 ICM A61K031-444
 ICS A61K031-4439; C07D043-14
 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; C07D0043-14 [ICS,7]
 IPCR C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0413-14 [I,A];
 C07D0417-00 [I,C]; C07D0417-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 19 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:144793 USPATFULL
 TI Glucocorticoid blocking agents for increasing blood-brain barrier
 permeability stan-261con
 IN Schatzberg, Alan F., Los Altos, CA, UNITED STATES
 Lindley, Steven E., Redwood City, CA, UNITED STATES
 Belanoff, Joseph K., Woodside, CA, UNITED STATES
 PI US 2005124533 A1 20050609
 AI US 2004-949739 A1 20040924 (10)
 RLI Continuation of Ser. No. US 2002-87227, filed on 27 Feb 2002, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 1544
 INCL INCLM: 514/008.000
 INCLS: 514/171.000; 514/034.000; 514/220.000; 514/192.000; 514/200.000;
 514/221.000; 514/317.000; 514/561.000; 514/154.000; 514/109.000;
 514/651.000; 514/251.000; 514/259.410; 514/217.000; 514/557.000;
 514/263.310
 NCL NCLM: 514/008.000

NCLS: 514/034.000; 514/109.000; 514/154.000; 514/171.000; 514/192.000;
514/200.000; 514/217.000; 514/220.000; 514/221.000; 514/251.000;
514/259.410; 514/263.310; 514/317.000; 514/557.000; 514/561.000;
514/651.000

IC [7]
ICM A61K038-16
ICS A61K031-704; A61K031-70; A61K031-66; A61K031-65; A61K031-59
IPCI A61K0038-16 [ICM,7]; A61K0031-704 [ICS,7]; A61K0031-70 [ICS,7];
A61K0031-66 [ICS,7]; A61K0031-65 [ICS,7]; A61K0031-59 [ICS,7]
IPCR A61K0031-135 [I,A]; A61K0031-135 [I,C]; A61K0031-545 [I,A];
A61K0031-545 [I,C]; A61K0031-56 [I,A]; A61K0031-56 [I,C];
A61K0031-65 [I,A]; A61K0031-65 [I,C]; A61K0031-66 [I,A];
A61K0031-66 [I,C]; A61K0031-7028 [I,C]; A61K0031-704 [I,A];
A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0038-14 [I,A];
A61K0038-14 [I,C]; A61K0045-00 [I,C]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 20 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:138662 USPATFULL
TI Substituted heterocyclic derivatives useful as antidiabetic and
antiobesity agents and method
IN Cheng, Peter T.W., Princeton, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Ding, Charles Z., Plano, TX, UNITED STATES
Herpin, Timothy F., Princeton, NJ, UNITED STATES
PI US 2005119312 A1 20050602
AI US 2004-16183 A1 20041217 (11)
RLI Division of Ser. No. US 2003-616283, filed on 8 Jul 2003, GRANTED, Pat.
No. US 6875782
PRAI US 2002-394553P 20020709 (60)
DT Utility
FS APPLICATION
LN.CNT 2939
INCL INCLM: 514/332.000
INCLS: 514/340.000; 546/256.000; 546/269.700; 546/271.400; 514/341.000
NCL NCLM: 514/332.000
NCLS: 514/340.000; 514/341.000; 546/256.000; 546/269.700; 546/271.400
IC [7]
ICM C07D417-14
ICS C07D413-14; A61K031-4439; A61K031-444
IPCI C07D0417-14 [ICM,7]; C07D0413-14 [ICS,7]; A61K0031-4439 [ICS,7];
A61K0031-444 [ICS,7]
IPCR C07D0233-00 [I,C]; C07D0233-54 [I,A]; C07D0249-00 [I,C];
C07D0249-06 [I,A]; C07D0263-00 [I,C]; C07D0263-32 [I,A];
C07D0271-00 [I,C]; C07D0271-06 [I,A]; C07D0413-00 [I,C];
C07D0413-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 21 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:99578 USPATFULL
TI HMG-CoA reductase inhibitors and method
IN Ahmad, Saleem, Wall, NJ, UNITED STATES
Robl, Jeffrey A., Newtown, PA, UNITED STATES
Ngu, Khehyong, Pennington, NJ, UNITED STATES
PI US 2005085497 A1 20050421
AI US 2004-946055 A1 20040921 (10)

PRAI US 2003-505893P 20030925 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2114
 INCL INCLM: 514/275.000
 INCLS: 544/330.000; 544/331.000; 514/340.000; 514/352.000; 546/282.100;
 546/304.000
 NCL NCLM: 514/275.000
 NCLS: 514/340.000; 514/352.000; 544/330.000; 544/331.000; 546/282.100;
 546/304.000
 IC [7]
 ICM A61K031-506
 ICS A61K031-505; C07D045-02
 IPCI A61K0031-506 [ICM,7]; A61K0031-505 [ICS,7]; C07D0045-02 [ICS,7]
 IPCR A61K0031-505 [I,A]; A61K0031-505 [I,C]; A61K0031-506 [I,A];
 A61K0031-506 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 22 OF 66 USPATFULL on STN

Full Text	Citing References
AN 2005:93409 USPATFULL	
TI Pyrazole derivatives as cannabinoid receptor modulators	
IN Pendri, Annapurna, South Glastonbury, CT, UNITED STATES	
Gerritz, Samuel, Guilford, CT, UNITED STATES	
Dodd, Dharmpal S., Princeton, NJ, UNITED STATES	
Sun, Chongqing, East Windsor, NJ, UNITED STATES	
<u>PI</u> <u>US 2005080087</u> A1 20050414	
<u>AI</u> <u>US 2004-959866</u> A1 20041006 (10)	
<u>PRAI</u> <u>US 2003-510445P</u> 20031010 (60)	
DT Utility	
FS APPLICATION	
LN.CNT 2510	
INCL INCLM: 514/252.050	
INCLS: 514/256.000; 514/341.000; 514/406.000; 544/238.000; 544/333.000; 546/275.400; 548/364.100; 548/374.100	
NCL NCLM: 514/252.050	
NCLS: 514/256.000; 514/341.000; 514/406.000; 544/238.000; 544/333.000; 546/275.400; 548/364.100; 548/374.100	
IC [7]	
ICM C07D043-04	
ICS A61K031-501; A61K031-506; A61K031-4439; A61K031-4152	
IPCI C07D0043-04 [ICM,7]; A61K0031-501 [ICS,7]; A61K0031-506 [ICS,7]; A61K0031-4439 [ICS,7]; A61K0031-4152 [ICS,7]	
IPCR C07D0231-00 [I,C]; C07D0231-14 [I,A]; C07D0401-00 [I,C]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0403-00 [I,C]; C07D0403-10 [I,A]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-10 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C]; C07D0409-10 [I,A]; C07D0413-00 [I,C]; C07D0413-10 [I,A]	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L31 ANSWER 23 OF 66 USPATFULL on STN

Full Text	Citing References
AN 2005:87817 USPATFULL	
TI Materials and methods for inhibiting the development of epilepsy	
IN Coulter, Douglas, Media, PA, UNITED STATES	
<u>PI</u> <u>US 2005075282</u> A1 20050407	

AI US 2004-956572 A1 20041001 (10)
PRAI US 2003-507679P 20031001 (60)
DT Utility
FS APPLICATION
LN.CNT 1367
INCL INCLM: 514/009.000
 INCLS: 514/023.000; 514/557.000; 514/575.000; 514/570.000
NCL NCLM: 514/009.000
 NCLS: 514/023.000; 514/557.000; 514/570.000; 514/575.000
IC [7]
 ICM A61K038-12
 ICS A61K031-70; A61K031-19
 IPCI A61K0038-12 [ICM,7]; A61K0031-70 [ICS,7]; A61K0031-19 [ICS,7]
 IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C]; A61K0031-185 [I,C];
 A61K0031-19 [I,A]; A61K0031-70 [I,A]; A61K0031-70 [I,C];
 A61K0045-00 [I,C]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 24 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2005:63617 USPATFULL
TI Pyrazine modulators of cannabinoid receptors
IN Ellsworth, Bruce A., Princeton, NJ, UNITED STATES
 Sun, Chongqing, East Windsor, NJ, UNITED STATES
 Pendri, Annapurna, Glastonbury, CT, UNITED STATES
PI US 2005054659 A1 20050310
AI US 2004-917199 A1 20040812 (10)
PRAI US 2003-495807P 20030815 (60)
DT Utility
FS APPLICATION
LN.CNT 2334
INCL INCLM: 514/255.050
 INCLS: 544/405.000
NCL NCLM: 514/255.050
 NCLS: 544/405.000
IC [7]
 ICM A61K031-497
 ICS A61K031-4965; C07D043-02
 IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICS,7]; C07D0043-02 [ICS,7]
 IPCR A61K [I,S]; A61K0031-4965 [I,A]; A61K0031-4965 [I,C];
 A61K0031-497 [I,A]; C07D0241-00 [I,A]; C07D0241-00 [I,C];
 C07D0241-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 25 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2005:44329 USPATFULL
TI Methods and materials for the treatment of pain comprising opioid
 antagonists
IN Burns, Lindsay H., San Francisco, CA, UNITED STATES
 Schoenhard, Grant L., San Carlos, CA, UNITED STATES
PI US 2005038062 A1 20050217
AI US 2004-825257 A1 20040414 (10)
PRAI US 2003-463004P 20030414 (60)
DT Utility
FS APPLICATION
LN.CNT 2752
INCL INCLM: 514/282.000

NCL NCLM: 514/282.000
 IC [7]
 ICM A61K031-485
 IPCI A61K0031-485 [ICM, 7]
 IPCR A61K0031-485 [I,A]; A61K0031-485 [I,C]; A61K0045-00 [I,C];
 A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 26 OF 66 USPATFULL on STN

Full Text	Cited References
--------------	---------------------

AN 2005:36871 USPATFULL
 TI Receptor mediated nanoscale copolymer assemblies for diagnostic imaging
 and therapeutic management of hyperlipidemia and infectious diseases
 IN Njemanze, Philip Chidi, Owerri, NIGERIA
 PI US 2005031544 A1 20050210
 AI US 2003-635820 A1 20030807 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 1344
 INCL INCLM: 424/009.322
 NCL NCLM: 424/009.322
 IC [7]
 ICM A61K049-00
 IPCI A61K0049-00 [ICM, 7]
 IPCR A61K0049-00 [I,A]; A61K0049-00 [I,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 27 OF 66 USPATFULL on STN

Full Text	Cited References
--------------	---------------------

AN 2005:31519 USPATFULL
 TI Carbinols for the treatment of neuropathic dysfunction
 IN Carliss, Richard, West Chester, PA, UNITED STATES
 Lee, David A.H., Chadds Ford, PA, UNITED STATES
 PA Endo Pharmaceuticals, Inc., a Delaware corporation, Chadds Ford, PA
 (U.S. corporation)
 PI US 2005026956 A1 20050203
 AI US 2004-923621 A1 20040820 (10)
 RLI Division of Ser. No. US 2002-272375, filed on 16 Oct 2002, GRANTED, Pat.
 No. US 6825217
 PRAI US 2001-329869P 20011016 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2412
 INCL INCLM: 514/326.000
 NCL NCLM: 514/326.000
 IC [7]
 ICM A61K031-453
 IPCI A61K0031-453 [ICM, 7]
 IPCR A61K0031-40 [I,A]; A61K0031-40 [I,C]; A61K0031-451 [I,A];
 A61K0031-451 [I,C]; A61K0031-4523 [I,C]; A61K0031-4535 [I,A];
 A61K0031-55 [I,A]; A61K0031-55 [I,C]; C07D0207-00 [I,C];
 C07D0207-08 [I,A]; C07D0211-00 [I,C]; C07D0211-22 [I,A];
 C07D0223-00 [I,C]; C07D0223-04 [I,A]; C07D0401-00 [I,C];
 C07D0401-04 [I,A]; C07D0405-00 [I,C]; C07D0405-04 [I,A];
 C07D0409-00 [I,C]; C07D0409-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 28 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:17384 USPATFULL

TI Tetrahydroquinoline derivatives as cannabinoid receptor modulators

IN Sun, Chongqing, East Windsor, NJ, UNITED STATES
 Sitkoff, Doree, Dresher, PA, UNITED STATES
 Ewing, William R., Yardley, PA, UNITED STATES
 Huang, Yanting, Pennington, NJ, UNITED STATES
 Ellsworth, Bruce A., Princeton, NJ, UNITED STATES
 Sulsky, Richard B., West Trenton, NJ, UNITED STATES

PI US 2005014786 A1 20050120

AI US 2004-889274 A1 20040712 (10)

PRAI US 2003-486774P 20030711 (60)

DT Utility

FS APPLICATION

LN.CNT 4140

INCL INCLM: 514/313.000
 INCLS: 546/159.000

NCL NCLM: 514/313.000
 NCLS: 546/159.000

IC [7]
 ICM A61K031-47
 ICS C07D215-38
 IPCI A61K0031-47 [ICM,7]; C07D0215-38 [ICS,7]
 IPCR A61K0031-47 [I,A]; A61K0031-47 [I,C]; C07D0215-00 [I,C];
 C07D0215-38 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 29 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:11735 USPATFULL

TI Tetrahydroquinoline derivatives as cannabinoid receptor modulators

IN Sher, Philip M., Plainsboro, NJ, UNITED STATES
 Sun, Chongqing, East Windsor, NJ, UNITED STATES
 Sulsky, Richard B., West Trenton, NJ, UNITED STATES
 Wu, Gang, Princeton, NJ, UNITED STATES
 Ewing, William R., Yardley, PA, UNITED STATES

PI US 2005009870 A1 20050113

AI US 2004-889268 A1 20040712 (10)

PRAI US 2003-486774P 20030711 (60)

DT Utility

FS APPLICATION

LN.CNT 2335

INCL INCLM: 514/312.000
 INCLS: 546/158.000

NCL NCLM: 514/312.000
 NCLS: 546/158.000

IC [7]
 ICM A61K031-47
 ICS C07D215-36
 IPCI A61K0031-47 [ICM,7]; C07D0215-36 [ICS,7]
 IPCR A61K0031-47 [I,A]; A61K0031-47 [I,C]; C07D0215-00 [I,C];
 C07D0215-36 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 30 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:335737 USPATFULL

TI Modulators of the glucocorticoid receptor and method
 IN Robinson, Leslie A., Del Mar, CA, UNITED STATES
 Rueter, Jaimie K., San Diego, CA, UNITED STATES
 Moree, Wilna J., San Diego, CA, UNITED STATES
PI US 2004266831 A1 20041230
AI US 2004-865443 A1 20040610 (10)
PRAI US 2003-477545P 20030611 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2079
 INCL INCLM: 514/341.000
 INCLS: 514/383.000
 NCL NCLM: 514/341.000
 NCLS: 514/383.000
 IC [7]
 ICM A61K031-4439
 ICS A61K031-4196
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4196 [ICS,7]
 IPCR A61K0031-4196 [I,A]; A61K0031-4196 [I,C]; A61K0031-4427 [I,C];
 A61K0031-4439 [I,A]; C07D0249-00 [I,C]; C07D0249-08 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 31 OF 66 USPATFULL on STN

Full Text	References
AN	2004:335664 USPATFULL
TI	Modulators of the glucocorticoid receptor and method
IN	Hadida-Ruah, Sara Sabine, San Diego, CA, UNITED STATES He, Xiaohui, San Diego, CA, UNITED STATES Nagasawa, Johnny Yasuo, San Diego, CA, UNITED STATES
<u>PI</u>	<u>US 2004266758</u> A1 20041230
<u>AI</u>	<u>US 2004-865444</u> A1 20040610 (10)
<u>PRAI</u>	<u>US 2003-477574P</u> 20030611 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2598
INCL	INCLM: 514/224.500 INCLS: 514/229.500; 514/249.000; 544/014.000; 544/099.000; 544/343.000
NCL	NCLM: 514/224.500 NCLS: 514/229.500; 514/249.000; 544/014.000; 544/099.000; 544/343.000
IC	[7] ICM A61K031-542 ICS A61K031-538; A61K031-498; C07D498-02; C07D491-02 IPCI A61K0031-542 [ICM,7]; A61K0031-538 [ICS,7]; A61K0031-498 [ICS,7]; C07D0498-02 [ICS,7]; C07D0491-02 [ICS,7] IPCR C07D0491-00 [I,C]; C07D0491-04 [I,A] CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 32 OF 66 USPATFULL on STN

Full Text	References
AN	2004:261970 USPATFULL
TI	Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
IN	Briggs, Michael, Shrewsbury, MA, UNITED STATES Hauser, Scott, St. Louis, MO, UNITED STATES Ornberg, Richard, Hayward, CA, UNITED STATES Koki, Alane, Marseille, FRANCE
PA	Pharmacia Corporation, Chesterfield, MO (U.S. corporation)
<u>PI</u>	<u>US 2004204472</u> A1 20041014

AI US 2004-773019 A1 20040205 (10)
PRAI US 2003-451885P 20030304 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5174
 INCL INCLM: 514/406.000
 INCLS: 514/457.000; 514/469.000
 NCL NCLM: 514/406.000
 NCLS: 514/457.000; 514/469.000
 IC [7]
 ICM A61K031-415
 ICS A61K031-366; A61K031-365
 IPCI A61K0031-415 [ICM,7]; A61K0031-366 [ICS,7]; A61K0031-365 [ICS,7]
 IPCR A61K0031-365 [I,A]; A61K0031-365 [I,C]; A61K0031-366 [I,A];
 A61K0031-366 [I,C]; A61K0031-415 [I,A]; A61K0031-415 [I,C];
 A61K0031-665 [I,A]; A61K0031-665 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 33 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:246716 USPATFULL
 TI Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
 IN Shapira, Nathan Andrew, Gainesville, FL, UNITED STATES
 Lessig, Mary Catherine, Seattle, WA, UNITED STATES
 McLaurin, Bonnie I., Gainesville, FL, UNITED STATES
PI US 2004191310 A1 20040930
AI US 2003-726327 A1 20031201 (10)
PRAI US 2002-430634P 20021202 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 785
 INCL INCLM: 424/464.000
 NCL NCLM: 424/464.000
 IC [7]
 ICM A61K009-20
 IPCI A61K0009-20 [ICM,7]
 IPCR A61K0031-35 [I,A]; A61K0031-35 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 34 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:242054 USPATFULL
 TI Use of glutamate antagonists for the treatment of cancer
 IN Ikonomidou, Hrissanthi, Joersstrasse 16, Berlin, GERMANY, FEDERAL REPUBLIC OF D-13505
PI US 6797692 B1 20040928
WO 2000024395 20000504
AI US 2001-830354 20010425 (9)
WO 1999-EP8004 19991022
PRAI EP 1998-250380 19981028
 DT Utility
 FS GRANTED
 LN.CNT 802
 INCL INCLM: 514/002.000
 INCLS: 514/080.000; 514/247.000
 NCL NCLM: 514/002.000
 NCLS: 514/080.000; 514/247.000

IC [7]
 ICM A61K038-00
 ICS A61K031-551; A61K031-498
 IPCI A61K0038-00 [ICM,7]; A61K0031-551 [ICS,7]; A61K0031-498 [ICS,7]
 IPCR A61K0031-439 [I,A]; A61K0031-439 [I,C]; A61K0031-498 [I,A];
 A61K0031-498 [I,C]; A61K0031-551 [I,C]; A61K0031-5513 [I,A]
 EXF 514/2; 514/80; 514/247; 424/451
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 35 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:221872 USPATFULL
 TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
 IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES
 Chen, Sean, Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES
 PI US 2004171644 A1 20040902
 AI US 2003-655876 A1 20030905 (10)
 RLI Division of Ser. No. US 2002-80981, filed on 22 Feb 2002, GRANTED, Pat. No. US 6653314 Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002 Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, ABANDONED
 PRAI US 1999-155400P 19990922 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5736
 INCL INCLM: 514/333.000
 INCLS: 514/342.000; 546/256.000; 546/270.400
 NCL NCLM: 514/333.000
 NCLS: 514/342.000; 546/256.000; 546/270.400
 IC [7]
 ICM C07D417-14
 ICS A61K031-4439; C07D417-04
 IPCI C07D0417-14 [ICM,7]; A61K0031-4439 [ICS,7]; C07D0417-04 [ICS,7]
 IPCR C07D0263-00 [I,C]; C07D0263-32 [I,A]; C07D0263-58 [I,A];
 C07D0277-00 [I,C]; C07D0277-24 [I,A]; C07D0413-00 [I,C];
 C07D0413-12 [I,A]; C07D0413-14 [I,A]; C07D0417-00 [I,C];
 C07D0417-04 [I,A]; C07D0417-12 [I,A]; C07D0495-00 [I,C];
 C07D0495-04 [I,A]; C07D0521-00 [I,A]; C07D0521-00 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 36 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:190787 USPATFULL
 TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
 IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES
 Chen, Sean, Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES
 PI US 2004147560 A1 20040729
 AI US 2003-737210 A1 20031216 (10)
 RLI Division of Ser. No. US 2002-81075, filed on 22 Feb 2002, GRANTED, Pat. No. US 6727271 Division of Ser. No. US 2001-812960, filed on 20 Mar

2001, GRANTED, Pat. No. US 6414002 Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, ABANDONED

PRAI US 1999-155400P 19990922 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5759
 INCL INCLM: 514/333.000
 INCLS: 514/340.000; 514/342.000; 546/256.000; 546/269.400; 546/271.400
 NCL NCLM: 514/333.000
 NCLS: 514/340.000; 514/342.000; 546/256.000; 546/269.400; 546/271.400
 IC [7]
 ICM A61K031-444
 ICS A61K031-4439; C07D417-14; C07D413-14
 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; C07D0417-14 [ICS,7];
 C07D0413-14 [ICS,7]
 IPCR C07D0263-00 [I,C]; C07D0263-32 [I,A]; C07D0263-58 [I,A];
 C07D0277-00 [I,C]; C07D0277-24 [I,A]; C07D0413-00 [I,C];
 C07D0413-12 [I,A]; C07D0413-14 [I,A]; C07D0417-00 [I,C];
 C07D0417-04 [I,A]; C07D0417-12 [I,A]; C07D0495-00 [I,C];
 C07D0495-04 [I,A]; C07D0521-00 [I,A]; C07D0521-00 [I,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 37 OF 66 USPATFULL on STN

Full Text	References
-----------	------------

AN	2004:172594	USPATFULL
TI	Modulators of the glucocorticoid receptor and method	
IN	Vaccaro, Wayne, Yardley, PA, UNITED STATES Yang, Bingwei Vera, Belle Mead, NJ, UNITED STATES Kim, Soong-Hoon, Titusville, NJ, UNITED STATES Huynh, Tram, Pennington, NJ, UNITED STATES Tortolani, David R., Skillman, NJ, UNITED STATES Leavitt, Kenneth J., Lawrenceville, NJ, UNITED STATES Li, Wenying, Middletown, CT, UNITED STATES Doweiko, Arthur M., Long Valley, NJ, UNITED STATES Chen, Xiao-Tao, Newark, DE, UNITED STATES Doweiko, Lidia, Long Valley, NJ, UNITED STATES	
<u>PI</u>	<u>US 2004132758</u>	A1 20040708
	<u>US 6995181</u>	B2 20060207
<u>AI</u>	<u>US 2003-621909</u>	A1 20030717 (10)
<u>PRAI</u>	<u>US 2002-396877P</u>	20020718 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	4692	
INCL	INCLM: 514/284.000 INCLS: 514/411.000; 546/074.000; 548/424.000	
NCL	NCLM: 514/371.000 NCLS: 548/195.000; 548/160.000; 548/222.000; 548/233.000; 548/332.500; 546/139.000; 546/152.000; 546/270.700; 546/285.000; 514/367.000; 514/377.000; 514/394.000; 514/398.000	
IC	[7] ICM A61K031-473 ICS A61K031-403; C07D209-56; C07D221-28 IPCI A61K0031-473 [ICM,7]; A61K0031-403 [ICS,7]; C07D0209-56 [ICS,7]; C07D0221-28 [ICS,7] IPCI-2 A61K0031-426 [I,A]; C07D0277-38 [I,A] IPCR A61K0031-403 [I,A]; A61K0031-403 [I,C]; A61K0031-473 [I,A]; A61K0031-473 [I,C]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; C07D0207-00 [I,C]; C07D0207-34 [I,A]; C07D0209-00 [I,C]; C07D0209-48 [I,A]; C07D0213-00 [I,C]; C07D0213-40 [I,A];	

C07D0213-75 [I,A]; C07D0213-82 [I,A]; C07D0215-00 [I,C];
 C07D0215-38 [I,A]; C07D0217-00 [I,C]; C07D0217-22 [I,A];
 C07D0231-00 [I,C]; C07D0231-16 [I,A]; C07D0233-00 [I,C];
 C07D0233-88 [I,A]; C07D0235-00 [I,C]; C07D0235-14 [I,A];
 C07D0235-30 [I,A]; C07D0239-00 [I,C]; C07D0239-42 [I,A];
 C07D0239-94 [I,A]; C07D0241-00 [I,C]; C07D0241-20 [I,A];
 C07D0261-00 [I,C]; C07D0261-12 [I,A]; C07D0261-14 [I,A];
 C07D0263-00 [I,C]; C07D0263-48 [I,A]; C07D0277-00 [I,C];
 C07D0277-46 [I,A]; C07D0277-64 [I,A]; C07D0285-00 [I,C];
 C07D0285-06 [I,A]; C07D0307-00 [I,C]; C07D0307-58 [I,A];
 C07D0317-00 [I,C]; C07D0317-58 [I,A]; C07D0333-00 [I,C];
 C07D0333-20 [I,A]; C07D0333-34 [I,A]; C07D0401-00 [I,C];
 C07D0401-04 [I,A]; C07D0405-00 [I,C]; C07D0405-04 [I,A];
 C07D0417-00 [I,C]; C07D0417-04 [I,A]; C07D0417-10 [I,A];
 C07D0417-12 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A];
 C07D0471-08 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A];
 C07D0495-00 [I,C]; C07D0495-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 38 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2004:159229 USPATFULL
 TI Combination therapy for the treatment of obesity
 IN Nargund, Ravi P., East Brunswick, NJ, UNITED STATES
 Van Der Ploeg, Leonardus H.T., Scotch Plains, NJ, UNITED STATES
 Fong, Tung M., Somerset, NJ, UNITED STATES
 MacNeil, Douglas J., Westfield, NJ, UNITED STATES
 Chen, Howard Y., Westfield, NJ, UNITED STATES
 Marsh, Donald J., Hillsborough, NJ, UNITED STATES
 Warmke, Jeffrey, Edison, NJ, UNITED STATES
 PI US 2004122033 A1 20040624
 AI US 2003-730704 A1 20031208 (10)
 PRAI US 2002-432063P 20021210 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3371
 INCL INCLM: 514/282.000
 INCLS: 514/571.000
 NCL NCLM: 514/282.000
 NCLS: 514/571.000
 IC [7]
 ICM A61K031-485
 ICS A61K031-19
 IPCI A61K0031-485 [ICM,7]; A61K0031-19 [ICS,7]
 IPCR A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0045-00 [I,C];
 A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 39 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2004:121157 USPATFULL
 TI HMG-CoA reductase inhibitors and method
 IN Robl, Jeffrey A., Newtown, PA, UNITED STATES
 Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES
 Sun, Chong-Qing, East Windsor, NJ, UNITED STATES
 PI US 2004092573 A1 20040513
US 6812345 B2 20041102
 AI US 2003-602752 A1 20030624 (10)

RLI Continuation-in-part of Ser. No. US 2001-875155, filed on 6 Jun 2001,
ABANDONED

PRAI US 2000-211595P 20000615 (60)

DT Utility

FS APPLICATION

LN.CNT 2545

INCL INCLM: 514/423.000

NCL NCLM: 546/089.000; 514/423.000
NCLS: 546/023.000; 546/080.000; 546/093.000

IC [7]
ICM A61K031-40
IPCI A61K0031-40 [ICM,7]
IPCI-2 C07D0491-044 [ICM,7]; C07D0495-04 [ICS,7]; C07D0471-04 [ICS,7];
C07F0009-28 [ICS,7]; A61K0031-4353 [ICS,7]
IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0491-00 [I,C];
C07D0491-04 [I,A]; C07D0491-10 [I,A]; C07D0495-00 [I,C];
C07D0495-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 40 OF 66 USPATFULL on STN

Full Text	References
AN 2004:83306	USPATFULL
TI	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
IN	Cheng, Peter T. W., Princeton, NJ, UNITED STATES Chen, Sean, Princeton, NJ, UNITED STATES Ding, Charles Z., Plano, TX, UNITED STATES Herpin, Timothy F., Princeton, NJ, UNITED STATES
PI	<u>US 2004063762</u> A1 20040401 <u>US 6875782</u> B2 20050405
AI	<u>US 2003-616283</u> A1 20030708 (10)
PRAI	<u>US 2002-394553P</u> 20020709 (60)
DT	Utility
FS	APPLICATION
LN.CNT	3048
INCL	INCLM: 514/333.000 INCLS: 514/340.000; 514/341.000; 546/256.000; 546/269.700; 546/271.400; 546/272.700
NCL	NCLM: 514/364.000; 514/333.000 NCLS: 514/359.000; 548/131.000; 548/255.000; 514/340.000; 514/341.000; 546/256.000; 546/269.700; 546/271.400; 546/272.700
IC	[7] ICM A61K031-444 ICS A61K031-4439; C07D417-02; C07D413-02; C07D413-14 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; C07D0417-02 [ICS,7]; C07D0413-02 [ICS,7]; C07D0413-14 [ICS,7] IPCI-2 A61K0031-4245 [ICM,7]; A61K0031-4192 [ICS,7]; C07D0271-06 [ICS,7]; C07D0249-04 [ICS,7] IPCR C07D0233-00 [I,C]; C07D0233-54 [I,A]; C07D0249-00 [I,C]; C07D0249-06 [I,A]; C07D0263-00 [I,C]; C07D0263-32 [I,A]; C07D0271-00 [I,C]; C07D0271-06 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 41 OF 66 USPATFULL on STN

Full Text	References
AN 2004:83244	USPATFULL
TI	Substituted heterocyclic derivatives useful as antidiabetic and

antiobesity agents and method

IN Cheng, Peter T.W., Princeton, NJ, UNITED STATES
 Chen, Sean, Princeton, NJ, UNITED STATES
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
 Ding, Charles Z., Plano, TX, UNITED STATES
 Herpin, Timothy F., Princeton, NJ, UNITED STATES
 Wu, Shung, Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES
 Wang, Wei, Princeton, NJ, UNITED STATES
 Ye, Xiang-Yang, Cranbury, NJ, UNITED STATES

PI US 2004063700 A1 20040401
AI US 2003-616365 A1 20030708 (10)
PRAI US 2002-394508P 20020709 (60)

DT Utility
 FS APPLICATION
 LN.CNT 9316
 INCL INCLM: 514/227.800
 INCLS: 514/235.500; 514/253.010; 544/060.000; 544/360.000; 544/126.000
 NCL NCLM: 514/227.800
 NCLS: 514/235.500; 514/253.010; 544/060.000; 544/126.000; 544/360.000
 IC [7]
 ICM C07D417-14
 ICS C07D413-14; C07D043-14; A61K031-541; A61K031-5377; A61K031-496
 IPCI C07D0417-14 [ICM,7]; C07D0413-14 [ICS,7]; C07D0043-14 [ICS,7];
 A61K0031-541 [ICS,7]; A61K0031-5377 [ICS,7]; A61K0031-496 [ICS,7]
 IPCR C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0413-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 42 OF 66 USPATFULL on STN

Full Text	Citing References
AN 2004:32074	USPATFULL
TI HMG-CoA reductase inhibitors and method	
IN Robl, Jeffrey A., Newtown, PA, UNITED STATES Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES Sun, Chong-Qing, East Windsor, NJ, UNITED STATES	
<u>PI</u> US 2004024216 A1 20040205	
<u>AI</u> US 2003-602753 A1 20030624 (10)	
<u>RLI</u> Division of Ser. No. <u>US 2001-8154</u> , filed on 4 Dec 2001, GRANTED, Pat. No. <u>US 6620821</u> Continuation-in-part of Ser. No. <u>US 2001-875218</u> , filed on 6 Jun 2001, ABANDONED	
<u>PRAI</u> US 2000-211594P 20000615 (60)	
DT Utility	
FS APPLICATION	
LN.CNT 2476	
INCL INCLM: 546/015.000 INCLS: 546/079.000	
NCL NCLM: 546/015.000 NCLS: 546/079.000	
IC [7] ICM C07D045-02 ICS C07D221-22 IPCI C07D0045-02 [ICM,7]; C07D0221-22 [ICS,7] IPCR C07D0221-00 [I,C]; C07D0221-10 [I,A]; C07D0221-16 [I,A]; C07D0221-20 [I,A]; C07D0405-00 [I,C]; C07D0405-06 [I,A]	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 43 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:7125 USPATFULL
 TI Modified-release vasopeptidase inhibitor formulation, combinations and method
 IN Slugg, Peter H., Princeton, NJ, UNITED STATES
 Jain, Nemichand B., West Windsor, NJ, UNITED STATES
 Krishna, Rajesh, West Windsor, NJ, UNITED STATES
 Jerzewski, Robert L., Belle Mead, NJ, UNITED STATES
 Smith, Ronald L., Yardley, PA, UNITED STATES
 Patel, Jatin M., West Windsor, NJ, UNITED STATES
 Malhotra, Bimal K., New Brunswick, NJ, UNITED STATES
PI US 2004005358 A1 20040108
AI US 2003-419397 A1 20030421 (10)
PRAI US 2002-374940P 20020423 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2536
 INCL INCLM: 424/468.000
 INCLS: 514/211.050
 NCL NCLM: 424/468.000
 NCLS: 514/211.050
 IC [7]
 ICM A61K031-554
 ICS A61K009-22
 IPCI A61K0031-554 [ICM,7]; A61K0009-22 [ICS,7]
 IPCR A61K0009-16 [I,A]; A61K0009-16 [I,C]; A61K0009-20 [I,A];
 A61K0009-20 [I,C]; A61K0009-50 [I,A]; A61K0009-50 [I,C];
 A61K0031-55 [I,A]; A61K0031-55 [I,C]; A61K0031-554 [I,A];
 A61K0031-554 [I,C]; A61K0045-00 [I,C]; A61K0045-06 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 44 OF 66 USPATFULL on STN

Full Text	Links References
--------------	---------------------

AN 2004:2472 USPATFULL
 TI Lactam glycogen phosphorylase inhibitors and method of use
 IN Sher, Philip, Plainsboro, NJ, UNITED STATES
 Wu, Gang, Princeton, NJ, UNITED STATES
 Stouch, Terry, West Windsor, NJ, UNITED STATES
 Ellsworth, Bruce, Princeton, NJ, UNITED STATES
PI US 2004002495 A1 20040101
AI US 2003-440851 A1 20030519 (10)
PRAI US 2002-382002P 20020520 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2640
 INCL INCLM: 514/228.200
 INCLS: 514/233.500; 514/233.800; 514/254.080; 544/060.000; 544/139.000;
 544/143.000; 544/370.000; 544/373.000
 NCL NCLM: 514/228.200
 NCLS: 514/233.500; 514/233.800; 514/254.080; 544/060.000; 544/139.000;
 544/143.000; 544/370.000; 544/373.000
 IC [7]
 ICM A61K031-541
 ICS A61K031-5377; A61K031-496; C07D417-02; C07D413-02; C07D043-02
 IPCI A61K0031-541 [ICM,7]; A61K0031-5377 [ICS,7]; A61K0031-496
 [ICS,7]; C07D0417-02 [ICS,7]; C07D0413-02 [ICS,7]; C07D0043-02
 [ICS,7]
 IPCR A61K0031-496 [I,A]; A61K0031-496 [I,C]; A61K0031-5375 [I,C];
 A61K0031-5377 [I,A]; A61K0031-541 [I,A]; A61K0031-541 [I,C];
 A61K0045-00 [I,C]; A61K0045-06 [I,A]; C07D0209-00 [I,C];

C07D0209-42 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A];
 C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0403-14 [I,A];
 C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0417-00 [I,C];
 C07D0417-12 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A];
 C07D0498-00 [I,C]; C07D0498-04 [I,A]; C07D0513-00 [I,C];
 C07D0513-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 45 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2003:232494 USPATFULL
 TI Glucocorticoid blocking agents for increasing blood-brain barrier permeability
 IN Schatzberg, Alan F., Los Altos, CA, UNITED STATES
 Lindley, Steven, Redwood City, CA, UNITED STATES
 Belanoff, Joseph K., Woodside, CA, UNITED STATES
 PI US 2003162695 A1 20030828
 AI US 2002-87227 A1 20020227 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 1551
 INCL INCLM: 514/008.000
 INCLS: 514/171.000; 514/027.000; 514/192.000; 514/200.000; 514/105.000;
 514/152.000; 514/037.000; 514/029.000; 514/283.000; 514/291.000;
 514/651.000; 424/649.000; 514/589.000
 NCL NCLM: 514/008.000
 NCLS: 424/649.000; 514/027.000; 514/029.000; 514/037.000; 514/105.000;
 514/152.000; 514/171.000; 514/192.000; 514/200.000; 514/283.000;
 514/291.000; 514/589.000; 514/651.000
 IC [7]
 ICM A61K038-14
 ICS A61K031-7048; A61K031-704; A61K031-66; A61K031-65; A61K031-56;
 A61K031-545; A61K031-135
 IPCI A61K0038-14 [ICM,7]; A61K0031-7048 [ICS,7]; A61K0031-704 [ICS,7];
 A61K0031-66 [ICS,7]; A61K0031-65 [ICS,7]; A61K0031-56 [ICS,7];
 A61K0031-545 [ICS,7]; A61K0031-135 [ICS,7]
 IPCR A61K0031-135 [I,A]; A61K0031-135 [I,C]; A61K0031-545 [I,A];
 A61K0031-545 [I,C]; A61K0031-56 [I,A]; A61K0031-56 [I,C];
 A61K0031-65 [I,A]; A61K0031-65 [I,C]; A61K0031-66 [I,A];
 A61K0031-66 [I,C]; A61K0031-7028 [I,C]; A61K0031-704 [I,A];
 A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0038-14 [I,A];
 A61K0038-14 [I,C]; A61K0045-00 [I,C]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 46 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2003:226419 USPATFULL
 TI Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
 IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES
 Hariharan, Narayanan, Richboro, PA, UNITED STATES
 PI US 2003158232 A1 20030821
US 6967212 B2 20051122
 AI US 2002-294525 A1 20021114 (10)
 RLI Continuation-in-part of Ser. No. US 2002-153454, filed on 22 May 2002,
 PENDING
 PRAI US 2001-294380P 20010530 (60)

DT Utility
 FS APPLICATION
 LN.CNT 3975
 INCL INCLM: 514/333.000
 INCLS: 514/340.000; 514/341.000; 514/342.000; 514/367.000; 514/375.000;
 514/397.000; 546/256.000; 546/269.700; 546/271.400; 546/272.700;
 548/203.000; 548/235.000
 NCL NCLM: 514/365.000; 514/333.000
 NCLS: 514/374.000; 548/194.000; 548/236.000; 514/340.000; 514/341.000;
 514/342.000; 514/367.000; 514/375.000; 514/397.000; 546/256.000;
 546/269.700; 546/271.400; 546/272.700; 548/203.000; 548/235.000
 IC [7]
 ICM A61K031-444
 ICS A61K031-4439; A61K031-427; A61K031-422; C07D417-02; C07D417-14;
 C07D413-14; C07D413-02
 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-427
 [ICS,7]; A61K0031-422 [ICS,7]; C07D0417-02 [ICS,7]; C07D0417-14
 [ICS,7]; C07D0413-14 [ICS,7]; C07D0413-02 [ICS,7]
 IPCI-2 A61K0031-421 [ICM,7]; C07D0263-32 [ICS,7]; C07D0413-10 [ICS,7];
 C07D0417-14 [ICS,7]
 IPCR C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0413-14 [I,A];
 C07D0417-00 [I,C]; C07D0417-14 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 47 OF 66 USPATFULL on STN

Full Text	Citing References
AN 2003:201346	USPATFULL
TI Use of matrix metalloproteinase inhibitors to mitigate nerve damage	
IN Noble, Linda Jeanne, San Francisco, CA, UNITED STATES	
Donovan, Frances Muriel, San Francisco, CA, UNITED STATES	
Werb, Zena, San Francisco, CA, UNITED STATES	
PA The Regents of the University of California (U.S. corporation)	
PI US 2003139332	A1 20030724
AI US 2002-192397	A1 20020709 (10)
PRAI US 2001-304306P	20010709 (60)
DT Utility	
FS APPLICATION	
LN.CNT 2849	
INCL INCLM: 514/012.000	
INCLS: 514/570.000; 514/602.000; 514/616.000; 514/575.000; 424/146.100	
NCL NCLM: 514/012.000	
NCLS: 424/146.100; 514/570.000; 514/575.000; 514/602.000; 514/616.000	
IC [7]	
ICM A61K039-395	
ICS A61K031-192; A61K031-19; A61K031-18; A61K031-16	
IPCI A61K0039-395 [ICM,7]; A61K0031-192 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-18 [ICS,7]; A61K0031-16 [ICS,7]	
IPCR A61K0031-16 [I,A]; A61K0031-16 [I,C]; A61K0031-18 [I,A]; A61K0031-18 [I,C]; A61K0031-185 [I,C]; A61K0031-192 [I,A]	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L31 ANSWER 48 OF 66 USPATFULL on STN

Full Text	Citing References
AN 2003:194141	USPATFULL
TI Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines	
IN Coe, Jotham W., Niantic, CT, UNITED STATES	
Sands, Steven B., Stonington, CT, UNITED STATES	

Harrigan, Edmund P., Old Lyme, CT, UNITED STATES
 O'Neill, Brian T., Old Saybrook, CT, UNITED STATES
 Watsky, Eric J., Stonington, CT, UNITED STATES

PA Pfizer Inc. (U.S. corporation)

PI US 2003133951 A1 20030717

AI US 2003-348381 A1 20030121 (10)

RLI Continuation of Ser. No. US 2000-740307, filed on 18 Dec 2000, ABANDONED

PRAI US 2000-195738P 20000407 (60)

DT Utility

FS APPLICATION

LN.CNT 1915

INCL INCLM: 424/239.100

INCLS: 514/312.000; 514/326.000; 514/317.000; 514/282.000; 514/169.000;
 514/221.000; 514/263.340; 424/760.000

NCL NCLM: 424/239.100

NCLS: 424/760.000; 514/169.000; 514/221.000; 514/263.340; 514/282.000;
 514/312.000; 514/317.000; 514/326.000

IC [7]

ICM A61K035-78

ICS A61K031-57; A61K031-5513; A61K031-4709; A61K031-485; A61K031-454;
 A61K039-08

IPCI A61K0035-78 [ICM,7]; A61K0031-57 [ICS,7]; A61K0031-5513 [ICS,7];
 A61K0031-4709 [ICS,7]; A61K0031-485 [ICS,7]; A61K0031-454
 [ICS,7]; A61K0039-08 [ICS,7]

IPCR A61K0031-4704 [I,A]; A61K0031-4704 [I,C]; A61K0031-4748 [I,A];
 A61K0031-4748 [I,C]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A];
 A61K0031-55 [I,A]; A61K0031-55 [I,C]; A61K0045-00 [I,C];
 A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 49 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2003:188513 USPATFULL

TI Substituted acid derivatives useful as antidiabetic and antiobesity
 agents and method

IN Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
 Jeon, Yoon T., Belle Mead, NJ, UNITED STATES

PI US 2003130306 A1 20030710

US 6673815 B2 20040106

AI US 2002-289053 A1 20021106 (10)

PRAI US 2001-333022P 20011106 (60)

DT Utility

FS APPLICATION

LN.CNT 1699

INCL INCLM: 514/301.000

INCLS: 514/302.000; 514/303.000; 546/113.000; 546/114.000; 546/115.000

NCL NCLM: 514/325.000; 514/301.000

NCLS: 514/375.000; 546/203.000; 548/217.000; 548/253.000; 514/302.000;
 514/303.000; 546/113.000; 546/114.000; 546/115.000

IC [7]

ICM C07D491-02

ICS C07D498-02; C07D471-02; A61K031-4745; A61K031-4743; A61K031-4741

IPCI C07D0491-02 [ICM,7]; C07D0498-02 [ICS,7]; C07D0471-02 [ICS,7];
 A61K0031-4745 [ICS,7]; A61K0031-4743 [ICS,7]; A61K0031-4741
 [ICS,7]

IPCI-2 C07D0263-52 [ICM,7]; A61K0031-445 [ICS,7]

IPCR A61K0031-421 [I,A]; A61K0031-421 [I,C]; A61K0045-00 [I,C];
 A61K0045-06 [I,A]; C07D0413-00 [I,C]; C07D0413-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 50 OF 66 USPATFULL on STN

Full Text	Citing References
AN	2003:141004 USPATFULL
TI	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
IN	Cheng, Peter T., Princeton, NJ, UNITED STATES Devasthale, Pratik, Plainsboro, NJ, UNITED STATES Jeon, Yoon, Belle Mead, NJ, UNITED STATES Chen, Sean, Princeton, NJ, UNITED STATES Zhang, Hao, Belle Mead, NJ, UNITED STATES
PI	US 2003096846 A1 20030522 US 6653314 B2 20031125
AI	US 2002-80981 A1 20020222 (10)
RLI	Continuation of Ser. No. <u>US 2001-812960</u> , filed on 20 Mar 2001, GRANTED, Pat. No. <u>US 6414002</u> Continuation-in-part of Ser. No. <u>US 2000-664598</u> , filed on 18 Sep 2000, PENDING
PRAI	<u>US 1999-155400P</u> 19990922 (60)
DT	Utility
FS	APPLICATION
LN.CNT	5718
INCL	INCLM: 514/340.000 INCLS: 514/342.000; 514/333.000; 514/365.000; 514/374.000; 546/256.000; 546/271.400; 546/270.400; 548/205.000; 548/235.000
NCL	NCLM: 514/256.000; 514/340.000 NCLS: 514/340.000; 514/374.000; 546/271.400; 548/235.000; 548/236.000; 514/333.000; 514/342.000; 514/365.000; 546/256.000; 546/270.400; 548/205.000
IC	[7] ICM A61K031-444 ICS A61K031-4439; C07D417-14; C07D413-14 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; C07D0417-14 [ICS,7]; C07D0413-14 [ICS,7] IPCI-2 A61K0031-505 [ICM,7]; A61K0031-44 [ICS,7]; C07D0413-10 [ICS,7] IPCR C07D0263-00 [I,C]; C07D0263-32 [I,A]; C07D0263-58 [I,A]; C07D0277-00 [I,C]; C07D0277-24 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0413-14 [I,A]; C07D0417-00 [I,C]; C07D0417-04 [I,A]; C07D0417-12 [I,A]; C07D0495-00 [I,C]; C07D0495-04 [I,A]; C07D0521-00 [I,A]; C07D0521-00 [I,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 51 OF 66 USPATFULL on STN

Full Text	Citing References
AN	2003:134647 USPATFULL
TI	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
IN	Cheng, Peter T., Princeton, NJ, UNITED STATES Zhang, Hao, Belle Mead, NJ, UNITED STATES Hariharan, Narayanan, Richboro, PA, UNITED STATES
PI	US 2003092736 A1 20030515
AI	US 2002-153454 A1 20020522 (10)
PRAI	<u>US 2001-294380P</u> 20010530 (60)
DT	Utility
FS	APPLICATION
LN.CNT	3412
INCL	INCLM: 514/333.000 INCLS: 514/340.000; 514/365.000; 514/374.000; 514/396.000; 546/256.000; 546/270.400; 546/271.400; 546/272.700; 546/276.400

NCL NCLM: 514/333.000
 NCLS: 514/340.000; 514/365.000; 514/374.000; 514/396.000; 546/256.000;
 546/270.400; 546/271.400; 546/272.700; 546/276.400

IC [7]
 ICM A61K031-444
 ICS A61K031-4439; A61K031-427; A61K031-422; A61K031-4178; C07D417-14;
 C07D413-14; C07D043-14
 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-427
 [ICS,7]; A61K0031-422 [ICS,7]; A61K0031-4178 [ICS,7]; C07D0417-14
 [ICS,7]; C07D0413-14 [ICS,7]; C07D0043-14 [ICS,7]
 IPCR C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0413-14 [I,A];
 C07D0417-00 [I,C]; C07D0417-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 52 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:134608 USPATFULL

TI Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method

IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES
 Wang, Wei, Princeton, NJ, UNITED STATES

PI US 2003092697 A1 20030515

AI US 2002-153342 A1 20020522 (10)

PRAI US 2001-294505P 20010530 (60)

DT Utility

FS APPLICATION

LN.CNT 2127

INCL INCLM: 514/210.200
 INCLS: 546/268.100; 546/256.000; 548/198.000; 548/235.000; 548/311.100;
 548/518.000

NCL NCLM: 514/210.200
 NCLS: 546/256.000; 546/268.100; 548/198.000; 548/235.000; 548/311.100;
 548/518.000

IC [7]
 ICM A61K031-4439
 ICS A61K031-444; C07D417-14; C07D413-14; C07D043-14
 IPCI A61K0031-4439 [ICM,7]; A61K0031-444 [ICS,7]; C07D0417-14 [ICS,7];
 C07D0413-14 [ICS,7]; C07D0043-14 [ICS,7]
 IPCR C07D0413-00 [I,C]; C07D0413-06 [I,A]; C07D0413-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 53 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:127720 USPATFULL

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES
 Chen, Sean, Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES

PI US 2003087935 A1 20030508
US 6727271 B2 20040427

AI US 2002-81075 A1 20020222 (10)

RLI Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING
 Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000,
 PENDING

PRAI US 1999-155400P 19990922 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5712
 INCL INCLM: 514/333.000
 INCLS: 514/342.000; 514/340.000; 514/365.000; 514/374.000; 546/256.000;
 546/269.400; 546/271.400; 548/235.000; 548/202.000
 NCL NCLM: 514/374.000; 514/333.000
 NCLS: 548/236.000; 514/340.000; 514/342.000; 514/365.000; 546/256.000;
 546/269.400; 546/271.400; 548/202.000; 548/235.000
 IC [7]
 ICM A61K031-444
 ICS A61K031-4439; C07D417-14; C07D413-14; A61K031-426
 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; C07D0417-14 [ICS,7];
 C07D0413-14 [ICS,7]; A61K0031-426 [ICS,7]
 IPCI-2 A61K0031-42 [ICM,7]; C07D0263-30 [ICS,7]
 IPCR C07D0263-00 [I,C]; C07D0263-32 [I,A]; C07D0263-58 [I,A];
 C07D0277-00 [I,C]; C07D0277-24 [I,A]; C07D0413-00 [I,C];
 C07D0413-12 [I,A]; C07D0413-14 [I,A]; C07D0417-00 [I,C];
 C07D0417-04 [I,A]; C07D0417-12 [I,A]; C07D0495-00 [I,C];
 C07D0495-04 [I,A]; C07D0521-00 [I,A]; C07D0521-00 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 54 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2003:100164 USPATFULL
 TI Substituted acid derivatives useful as antidiabetic and antiobesity
 agents and method
 IN Cheng, Peter T., Princeton, NJ, UNITED STATES
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES
 Chen, Sean, Princeton, NJ, UNITED STATES
 Zhang, Hao, Belle Mead, NJ, UNITED STATES
 PI US 2003069275 A1 20030410
US 6919358 B2 20050719
 AI US 2002-80965 A1 20020222 (10)
 RLI Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING
 Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000,
 PENDING
PRAI US 1999-155400P 19990922 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5710
 INCL INCLM: 514/333.000
 INCLS: 514/340.000; 514/365.000; 514/374.000; 546/256.000; 546/271.400;
 546/269.700; 548/202.000; 548/235.000
 NCL NCLM: 514/340.000; 514/333.000
 NCLS: 546/271.400; 514/365.000; 514/374.000; 546/256.000; 546/269.700;
 548/202.000; 548/235.000
 IC [7]
 ICM A61K031-4439
 ICS A61K031-444; A61K031-426; A61K031-421
 IPCI A61K0031-4439 [ICM,7]; A61K0031-444 [ICS,7]; A61K0031-426
 [ICS,7]; A61K0031-421 [ICS,7]
 IPCI-2 A61K0031-443 [ICM,7]; C07D0413-12 [ICS,7]
 IPCR C07D0263-00 [I,C]; C07D0263-32 [I,A]; C07D0263-58 [I,A];
 C07D0277-00 [I,C]; C07D0277-24 [I,A]; C07D0413-00 [I,C];
 C07D0413-12 [I,A]; C07D0413-14 [I,A]; C07D0417-00 [I,C];
 C07D0417-04 [I,A]; C07D0417-12 [I,A]; C07D0495-00 [I,C];

C07D0495-04 [I,A]; C07D0521-00 [I,A]; C07D0521-00 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 55 OF 66 USPATFULL on STN

	Full Text	Citing References
AN	2003:92739	USPATFULL
TI	SOLID CARRIERS FOR IMPROVED DELIVERY OF HYDROPHOBIC ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS	
IN	Patel, Mahesh V., Salt Lake City, UT, UNITED STATES Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES	
PI	US 2003064097	A1 20030403
	US 6569463	B2 20030527
AI	US 2001-800593	A1 20010306 (9)
RLI	Division of Ser. No. <u>US 1999-447690</u> , filed on 23 Nov 1999, GRANTED, Pat. No. <u>US 6248363</u>	
DT	Utility	
FS	APPLICATION	
LN.CNT	3863	
INCL	INCLM: 424/465.000	
NCL	NCLM: 424/497.000; 424/465.000	
	NCLS: 424/422.000; 424/427.000; 424/430.000; 424/433.000; 424/434.000; 424/435.000; 424/436.000; 424/441.000; 424/451.000; 424/457.000; 424/463.000; 424/464.000; 424/465.000; 424/466.000; 424/470.000; 424/474.000; 424/476.000; 424/482.000; 424/489.000; 424/490.000; 424/498.000; 514/773.000; 514/779.000; 514/784.000; 514/785.000; 514/786.000; 977/906.000; 977/927.000	
IC	[7]	
	ICM	A61K009-20
	ICS	A61K009-16; A61K009-50
	IPCI	A61K0009-20 [ICM,7]; A61K0009-16 [ICS,7]; A61K0009-50 [ICS,7]
	IPCI-2	A61K0009-16 [ICM,7]; A61K0009-28 [ICS,7]; A61K0009-32 [ICS,7]; A61K0009-52 [ICS,7]; A61K0009-56 [ICS,7]; A61K0009-58 [ICS,7]
	IPCR	A61K0009-16 [I,A]; A61K0009-16 [I,C]; A61K0009-48 [I,A]; A61K0009-48 [I,C]; A61K0009-50 [N,A]; A61K0009-50 [N,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 56 OF 66 USPATFULL on STN

	Full Text	Citing References
AN	2002:297568	USPATFULL
TI	Cyclodextrin ethers	
IN	Buchanan, Charles M., Kingsport, TN, United States Dixon, Jr., Daniel W., Church Hill, TN, United States Lambert, Juanelle L., Gray, TN, United States Offerman, Ricky J., Kingsport, TN, United States Wood, Matthew D., Gray, TN, United States	
PA	Eastman Chemical Company, Kingsport, TN, United States (U.S. corporation)	
PI	US 6479467	B1 20021112
AI	US 1999-461226	19991216 (9)
DT	Utility	
FS	GRANTED	
LN.CNT	1134	
INCL	INCLM: 514/058.000	
	INCLS: 536/103.000; 536/124.000; 525/054.240	
NCL	NCLM: 514/058.000	
	NCLS: 525/054.240; 536/103.000; 536/124.000	
IC	[7]	
	ICM	A61K031-715

ICS C08B037-16
 IPCI A61K0031-715 [ICM,7]; C08B0037-16 [ICS,7]
 IPCR C08B0037-00 [I,A]; C08B0037-00 [I,C]; C08B0037-16 [I,A]
 EXF 514/58; 536/103; 536/124; 525/54.24
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 57 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:199156 USPATFULL
 TI EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS
 IN CHEN, FENG-JING, SALT LAKE CITY, UT, UNITED STATES
 PATEL, MAHESH V., SALT LAKE CITY, UT, UNITED STATES
 PI US 2002107265 A1 20020808
US 6720001 B2 20040413
 AI US 1999-420159 A1 19991018 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 2236
 INCL INCLM: 514/310.000
 NCL NCLM: 424/455.000; 514/310.000
 NCLS: 424/400.000; 424/450.000; 424/456.000
 IC [7]
 ICM A61K031-47
 ICS A01N043-42
 IPCI A61K0031-47 [ICM,7]; A01N0043-42 [ICS,7]
 IPCI-2 A61K0009-127 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-66 [ICS,7]
 IPCR A61K0009-107 [I,A]; A61K0009-107 [I,C]; A61K0031-185 [I,C];
 A61K0031-20 [I,A]; A61K0031-352 [I,C]; A61K0031-355 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 58 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:179187 USPATFULL
 TI HMG-CoA reductase inhibitors and method
 IN Robl, Jeffrey A., Newtown, PA, UNITED STATES
 Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES
 Sun, Chong-Qing, East Windsor, NJ, UNITED STATES
 PI US 2002094977 A1 20020718
US 6627636 B2 20030930
 AI US 2001-7407 A1 20011204 (10)
 RLI Continuation-in-part of Ser. No. US 2001-875155, filed on 6 Jun 2001,
 PENDING
 PRAI US 2000-211595P 20000615 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2539
 INCL INCLM: 514/215.000
 INCLS: 514/291.000; 546/080.000; 540/586.000
 NCL NCLM: 514/291.000; 514/215.000
 NCLS: 514/213.010; 514/292.000; 540/577.000; 546/080.000; 546/081.000;
 546/089.000; 546/093.000; 540/586.000
 IC [7]
 ICM C07D498-02
 ICS A61K031-55; A61K031-4745
 IPCI C07D0498-02 [ICM,7]; A61K0031-55 [ICS,7]; A61K0031-4745 [ICS,7]
 IPCI-2 A61K0031-4353 [ICM,7]; A61K0031-4365 [ICS,7]; C07D0491-044
 [ICS,7]; C07D0495-04 [ICS,7]; A61P0003-06 [ICS,7]
 IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0491-00 [I,C];

C07D0491-04 [I,A]; C07D0491-10 [I,A]; C07D0495-00 [I,C];
C07D0495-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 59 OF 66 USPATFULL on STN

Full Text	Citing References
AN	2002:119913 USPATFULL
TI	HMG-CoA reductase inhibitors and method
IN	Robl, Jeffrey A., Newtown, PA, UNITED STATES Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES Sun, Chong-Qing, East Windsor, NJ, UNITED STATES
PI	US 2002061901 A1 20020523 US 6620821 B2 20030916
AI	US 2001-8154 A1 20011204 (10)
RLI	Continuation-in-part of Ser. No. US 2001-875218, filed on 6 Jun 2001, PENDING
PRAI	US 2000-211594P 20000615 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2458
INCL	INCLM: 514/290.000 INCLS: 514/278.000; 546/015.000; 546/079.000; 546/093.000
NCL	NCLM: 514/290.000 NCLS: 546/093.000; 546/101.000; 546/111.000; 514/278.000; 546/015.000; 546/079.000
IC	[7] ICM A61K031-4747 ICS A61K031-473; C07D221-20; C07D221-08 IPCI A61K0031-4747 [ICM,7]; A61K0031-473 [ICS,7]; C07D0221-20 [ICS,7]; C07D0221-08 [ICS,7] IPCI-2 A61K0031-435 [ICM,7]; A61K0031-473 [ICS,7]; C07D0221-06 [ICS,7]; C07D0405-06 [ICS,7]; A61P0003-06 [ICS,7] IPCR C07D0221-00 [I,C]; C07D0221-10 [I,A]; C07D0221-16 [I,A]; C07D0221-20 [I,A]; C07D0405-00 [I,C]; C07D0405-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 60 OF 66 USPATFULL on STN

Full Text	Citing References
AN	2002:48634 USPATFULL
TI	HMG-CoA reductase inhibitors and method
IN	Robl, Jeffrey A., Newtown, PA, UNITED STATES Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES Sun, Chong-Qing, East Windsor, NJ, UNITED STATES
PI	US 2002028826 A1 20020307
AI	US 2001-875218 A1 20010606 (9)
PRAI	US 2000-211594P 20000615 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2414
INCL	INCLM: 514/290.000 INCLS: 546/079.000; 546/093.000
NCL	NCLM: 514/290.000 NCLS: 546/079.000; 546/093.000
IC	[7] ICM C07D221-06 ICS A61K031-473 IPCI C07D0221-06 [ICM,7]; A61K0031-473 [ICS,7] IPCR C07D0221-00 [I,C]; C07D0221-10 [I,A]; C07D0221-16 [I,A];

C07D0221-20 [I,A]; C07D0405-00 [I,C]; C07D0405-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 61 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2002:22498 USPATFULL
TI HMG-CoA reductase inhibitors and method
IN Robl, Jeffrey A., Newton, PA, UNITED STATES
Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES
Sun, Chong-Qing, East Windsor, NJ, UNITED STATES
PI US 2002013334 A1 20020131
AI US 2001-875155 A1 20010606 (9)
PRAI US 2000-211595P 20000615 (60)
DT Utility
FS APPLICATION
LN.CNT 2416
INCL INCLM: 514/291.000
INCLS: 546/080.000
NCL NCLM: 514/291.000
NCLS: 546/080.000
IC [7]
ICM A61K031-4741
ICS A61K031-4743; C07D491-02
IPCI A61K0031-4741 [ICM,7]; A61K0031-4743 [ICS,7]; C07D0491-02 [ICS,7]
IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0491-00 [I,C];
C07D0491-04 [I,A]; C07D0491-10 [I,A]; C07D0495-00 [I,C];
C07D0495-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 62 OF 66 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2001:194428 USPATFULL
TI Pharmaceutical composition for treatment of acute, chronic pain and/or
neuropathic pain and migraines
IN Coe, Jotham W., Niantic, CT, United States
Sands, Steven B., Stonington, CT, United States
Harrigan, Edmund P., Old Lyme, CT, United States
O'Neill, Brian T., Old Saybrook, CT, United States
Watsky, Eric J., Stonington, CT, United States
PI US 2001036943 A1 20011101
AI US 2000-740307 A1 20001218 (9)
PRAI US 2000-195738P 20000407 (60)
DT Utility
FS APPLICATION
LN.CNT 1917
INCL INCLM: 514/220.000
INCLS: 514/300.000; 514/304.000; 514/312.000; 514/235.800; 514/294.000;
514/217.000
NCL NCLM: 514/220.000
NCLS: 514/217.000; 514/235.800; 514/294.000; 514/300.000; 514/304.000;
514/312.000
IC [7]
ICM A61K031-4704
ICS A61K031-4748; A61K031-5377; A61K031-5513; A61K031-55
IPCI A61K0031-4704 [ICM,7]; A61K0031-4748 [ICS,7]; A61K0031-5377
[ICS,7]; A61K0031-5513 [ICS,7]; A61K0031-55 [ICS,7]
IPCR A61K0031-4704 [I,A]; A61K0031-4704 [I,C]; A61K0031-4748 [I,A];
A61K0031-4748 [I,C]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A];

A61K0031-55 [I,A]; A61K0031-55 [I,C]; A61K0045-00 [I,C];
A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 63 OF 66 USPAT2 on STN

Full Text	Citing References
AN	2003:226419 USPAT2
TI	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
IN	Cheng, Peter T., Princeton, NJ, UNITED STATES Zhang, Hao, Belle Mead, NJ, UNITED STATES
PA	Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI	US 6967212 B2 20051122
AI	US 2002-294525 20021114 (10)
RLI	Continuation-in-part of Ser. No. <u>US 2002-153454</u> , filed on 22 May 2002, ABANDONED
PRAI	<u>US 2001-294380P</u> 20010530 (60)
DT	Utility
FS	GRANTED
LN.CNT	3842
INCL	INCLM: 514/365.000 INCLS: 514/374.000; 548/194.000; 548/236.000
NCL	NCLM: 514/365.000; 514/333.000 NCLS: 514/374.000; 548/194.000; 548/236.000; 514/340.000; 514/341.000; 514/342.000; 514/367.000; 514/375.000; 514/397.000; 546/256.000; 546/269.700; 546/271.400; 546/272.700; 548/203.000; 548/235.000
IC	[7] ICM A61K031-421 ICS C07D263-32; C07D413-10; C07D417-14 IPCI A61K0031-444 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-427 [ICS,7]; A61K0031-422 [ICS,7]; C07D0417-02 [ICS,7]; C07D0417-14 [ICS,7]; C07D0413-14 [ICS,7]; C07D0413-02 [ICS,7] IPCI-2 A61K0031-421 [ICM,7]; C07D0263-32 [ICS,7]; C07D0413-10 [ICS,7]; C07D0417-14 [ICS,7] IPCR C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0413-14 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
EXF	548/194; 548/236; 514/365; 514/374

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 64 OF 66 USPAT2 on STN

Full Text	Citing References
AN	2003:188513 USPAT2
TI	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
IN	Devasthale, Pratik, Plainsboro, NJ, United States Jeon, Yoon T., Belle Mead, NJ, United States
PA	Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI	US 6673815 B2 20040106
AI	US 2002-289053 20021106 (10)
PRAI	<u>US 2001-333022P</u> 20011106 (60)
DT	Utility
FS	GRANTED
LN.CNT	1672
INCL	INCLM: 514/325.000 INCLS: 514/375.000; 546/203.000; 548/217.000; 548/253.000
NCL	NCLM: 514/325.000; 514/301.000

NCLS: 514/375.000; 546/203.000; 548/217.000; 548/253.000; 514/302.000;
514/303.000; 546/113.000; 546/114.000; 546/115.000

IC [7]
ICM C07D263-52
ICS A61K031-445
IPCI C07D0491-02 [ICM,7]; C07D0498-02 [ICS,7]; C07D0471-02 [ICS,7];
A61K0031-4745 [ICS,7]; A61K0031-4743 [ICS,7]; A61K0031-4741
[ICS,7]
IPCI-2 C07D0263-52 [ICM,7]; A61K0031-445 [ICS,7]
IPCR A61K0031-421 [I,A]; A61K0031-421 [I,C]; A61K0045-00 [I,C];
A61K0045-06 [I,A]; C07D0413-00 [I,C]; C07D0413-06 [I,A]
EXF 514/375; 514/325; 548/217; 548/253; 546/203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 65 OF 66 USPAT2 on STN

Full Text	Citing References
AN	2002:199156 USPAT2
TI	Emulsion compositions for polyfunctional active ingredients
IN	Chen, Feng-Jing, Salt Lake City, UT, United States Patel, Mahesh V., Salt Lake City, UT, United States
PA	Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI	US 6720001 B2 20040413
AI	US 1999-420159 19991018 (9)
DT	Utility
FS	GRANTED
LN.CNT	1758
INCL	INCLM: 424/455.000 INCLS: 424/450.000; 424/456.000; 424/400.000
NCL	NCLM: 424/455.000; 514/310.000 NCLS: 424/400.000; 424/450.000; 424/456.000
IC	[7] ICM A61K009-127 ICS A61K009-48; A61K009-66 IPCI A61K0031-47 [ICM,7]; A01N0043-42 [ICS,7] IPCI-2 A61K0009-127 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-66 [ICS,7] IPCR A61K0009-107 [I,A]; A61K0009-107 [I,C]; A61K0031-185 [I,C]; A61K0031-20 [I,A]; A61K0031-352 [I,C]; A61K0031-355 [I,A] EXF 514/937; 514/570; 514/458; 424/45; 424/400; 424/450; 424/451; 424/455 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 66 OF 66 USPAT2 on STN

Full Text	Citing References
AN	2001:114624 USPAT2
TI	Anticonvulsant containing composition for treating neuropathic pain
IN	Caruso, Frank S., Colts Neck, NJ, United States Minn, Fredrick L., Blue Bell, PA, United States Lyle, John W., Belmar, NJ, United States
PA	Endo Pharmaceuticals Inc., Chadds Ford, PA, United States (U.S. corporation)
PI	US 6406716 B2 20020618
AI	US 2001-780858 20010209 (9)
RLI	Continuation of Ser. No. <u>US 1999-253598</u> , filed on 22 Feb 1999, now patented, Pat. No. <u>US 6187338</u> Continuation of Ser. No. <u>WO 1997-US14680</u> , filed on 21 Aug 1997
PRAI	<u>US 1996-24508P</u> 19960823 (60)
DT	Utility
FS	GRANTED
LN.CNT	611

INCL INCLM: 424/468.000
 INCLS: 424/455.000; 424/457.000; 424/464.000
 NCL NCLM: 424/468.000; 514/216.000
 NCLS: 424/455.000; 424/457.000; 424/464.000; 424/709.000; 514/282.000;
 514/386.000
 IC [7]
 ICM A61K009-22
 ICS A61K009-52
 IPCI A61K0033-04 [ICM,7]; A61K0031-55 [ICS,7]; A61K0031-485 [ICS,7]
 IPCI-2 A61K0009-22 [ICM,7]; A61K0009-52 [ICS,7]
 IPCR A61K0045-00 [I,C]; A61K0045-06 [I,A]
 EXF 424/457; 424/468; 424/489; 424/455; 424/464; 424/423; 424/451; 424/456
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 22:19:33 ON 02 MAR 2006)

FILE 'REGISTRY' ENTERED AT 22:19:40 ON 02 MAR 2006

E TOPIRAMATE/CN

L1 1 S E3

FILE 'MRCK' ENTERED AT 22:20:14 ON 02 MAR 2006

L2 1 S L1

FILE 'MEDLINE' ENTERED AT 22:20:41 ON 02 MAR 2006

L3 3 S (ANTICONVULANT?)

L4 32693 S ANTICONVULSANT?

L5 33208 S ANTICONVULS?

L6 33208 S L4 OR L5

L7 1300 S TOPIRAMATE

L8 1134070 S (CANCER OR TUMOR?)

L9 598 S L6 AND L8

L10 10 S L7 AND L8

L11 11 S FRUCTOPYRANOSE SULFAMATE

L12 0 S L8 AND L11

L13 52 S FRUCTOPYRANOSE?

L14 1 S L8 AND L13

FILE 'USPATFULL, USPAT2' ENTERED AT 22:28:09 ON 02 MAR 2006

L15 7379 S ANTICONVULSANT?

L16 7977 S ANTICONVULS?

L17 994 S TOPIRAMATE

L18 157015 S (CANCER OR TUMOR?)

L19 99 S FRUCTOPYRANOSE SULFAMATE

L20 7977 S L15 OR L16

L21 2842 S L18 AND L20

L22 629 S L17 AND L18

L23 17 S L18 AND L19

L24 649 S ANTICONVULSANT?/CLM

L25 727 S ANTICONVULS?/CLM

L26 266 S TOPIRAMATE/CLM

L27 34083 S (CANCER OR TUMOR?)/CLM

L28 13 S FRUCTOPYRANOSE SULFAMATE/CLM

L29 727 S L24 OR L25

L30 75 S L27 AND L29

L31 66 S L26 AND L27

L32 0 S L27 AND L28

=> d l3l an ti pi kwic 34 56 64 66

L31 ANSWER 34 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:242054 USPATFULL

TI Use of glutamate antagonists for the treatment of cancer

PI US 6797692 B1 20040928

WO 2000024395 20000504

CLM What is claimed is:

1. A method of treating **cancer** comprising administering an inhibitor of the interaction of glutamate with the AMPA receptor complex.

2. A method according to claim 1, wherein **cancer** includes any disorder that results from abnormal and uncontrolled cell growth with resulting invasion and destruction of neighboring tissue which. . .

. . . acid monohydrate (YM872), (3RS,4aRS,6RS,8aRS)-6-(2-(1H-tetrazole-5-yl)ethyl)-decahydroiso-quinoline-3-carboxylic acid (LY293558), 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX), 8-methyl-5-(4-(N,N-dimethylsulphamoyl)phenyl)-6,7,8,9-tetra-hydro-1H-pyrrolo[3,2h]-isoquinoline-2,3-dione-3-O-(3-hydroxybutyric acid-2-yl)oxime (NS 1209), 6,7-dichloro-2-(1H)-quinolinone-3-phosphonate (S 17625-2), [1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-1-yl]methyl-phosphonate (ZK200775), 1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazepine (GYKI52466), **topiramate** and 5-{2-[2-(N,N-dimethylamino)ethyl]oxy-phenyl}-3-phenyl-1,2,4-oxadiazol, 1-(4-aminophenyl)-3-methylcarbamoyl-7,8(GYKI 53655), (-)1-(4-aminophenyl)-4-methyl-7,8-mehtylenedioxy-4,5-dihydro-3-methylcarbamoyl-2,3-benzodiazepine (GYKI53773), dimethyl-{2-[2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-phenoxy]ethyl}-amine hydrochloride (BIIR 561).

. . . 1 wherein the inhibitor is combined with: a cytostatic agent; an immunomodulating agent; a physical measure for the treatment of **cancer**; or a mono- or polyclonal antibody antisense therapeutic **cancer** vaccine, or gene therapy.

L31 ANSWER 56 OF 66 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:297568 USPATFULL

TI Cyclodextrin ethers

PI US 6479467 B1 20021112

CLM What is claimed is:

. . . The inclusion complex according to claim 23, wherein the guest molecule is selected from the group consisting of anti-viral agents, anti-**cancer** agents, agents for treatment of neural disorders, anti-microbial and anti-fungal agents, steroids, non-steroid anti-rheumatic agents, cardiac glycosides, oligionucleotides, derivatives of. . .

. . . prostaglandin, ibuprofen, hydrocortisone, sodium loxoprofen, testosterone, piroxicam, benexate, iodine, dexamethasone, nitroglycerin, cefotiam hexetil HCl, thyaprofenic, chlordiazepoxide, itraconazole, garlic oil, and **topiramate**.

. . . The inclusion complex according to claim 27, wherein the guest molecule is selected from the group consisting of anti-viral agents, anti-**cancer** agents, agents for treatment of neural disorders, anti-microbial and anti-fungal agents, steroids, non-steroid

anti-rheumatic agents, cardiac glycosides, oligionucleotides, derivatives of. . . .
 . . . prostaglandin, ibuprofen, hydrocortisone, sodium loxoprofen, testosterone, piroxicam, benexate, iodine, dexamethasone, nitroglycerin, cefotiam hexetil HCl, thyaprofenic, chlordiazepoxide, itraconazole, garlic oil, and **topiramate**.

L31 ANSWER 64 OF 66 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2003:188513 USPAT2

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

PI US 6673815 B2 20040106

CLM What is claimed is:

24. The combination as defined in claim 23 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, **topiramate**, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol.

32. The method of treating a malignant disease, wherein the disease is a liposarcoma or an epithelial **tumor**.

33. The method as defined in claim 32 wherein the epithelial **tumor** is a **tumor** of the breast, prostate, colon, ovaries, stomach or lung.

L31 ANSWER 66 OF 66 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2001:114624 USPAT2

TI Anticonvulsant containing composition for treating neuropathic pain

PI US 6406716 B2 20020618

CLM What is claimed is:

. . . exhibit, neuropathic pain which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium,

. . . neuropathic pain-alleviating composition which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium,

. . . neuropathic pain-alleviating composition which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium,

. . . 23. A method of alleviating neuropathic pain in a mammal exhibiting, or about to exhibit, neuropathic pain caused by a **tumor** which comprises administering to the mammal a neuropathic pain-alleviating composition which comprises (a) gabapentin and (b) at least one

nontoxic. . . .

- . . . 25. A method of alleviating neuropathic pain in a mammal exhibiting, or about to exhibit, neuropathic pain caused by a **tumor** which comprises administering to the mammal a neuropathic pain-alleviating composition which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, . . .
- . . . neuropathic pain-alleviating composition which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, . . .
- . . . neuropathic pain-alleviating composition which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, . . .
- . . . neuropathic pain-alleviating composition which comprises (a) at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, **topiramate**, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, . . .

=> d his fulli

(FILE 'HOME' ENTERED AT 22:19:33 ON 02 MAR 2006)

FILE 'REGISTRY' ENTERED AT 22:19:40 ON 02 MAR 2006

E TOPIRAMATE/CN

L1 1 SEA TOPIRAMATE/CN
D

FILE 'MRCK' ENTERED AT 22:20:14 ON 02 MAR 2006

L2 1 SEA L1
D

FILE 'MEDLINE' ENTERED AT 22:20:41 ON 02 MAR 2006

L3 3 SEA (ANTICONVULANT?)
L4 32693 SEA ANTICONVULSANT?
L5 33208 SEA ANTICONVULS?
L6 33208 SEA L4 OR L5
L7 1300 SEA TOPIRAMATE
L8 1134070 SEA (CANCER OR TUMOR?)
L9 598 SEA L6 AND L8
L10 10 SEA L7 AND L8
D 1-10
D KWIC 6
L11 11 SEA FRUCTOPYRANOSE SULFAMATE
L12 0 SEA L8 AND L11

L13 52 SEA FRUCTOPYRANOSE?
 L14 1 SEA L8 AND L13
 D

FILE 'USPATFULL, USPAT2' ENTERED AT 22:28:09 ON 02 MAR 2006

L15 7379 SEA ANTICONVULSANT?
 L16 7977 SEA ANTICONVULS?
 L17 994 SEA TOPIRAMATE
 L18 157015 SEA (CANCER OR TUMOR?)
 L19 99 SEA FRUCTOPYRANOSE SULFAMATE
 L20 7977 SEA L15 OR L16
 L21 2842 SEA L18 AND L20
 L22 629 SEA L17 AND L18
 L23 17 SEA L18 AND L19
 L24 649 SEA ANTICONVULSANT?/CLM
 L25 727 SEA ANTICONVULS?/CLM
 L26 266 SEA TOPIRAMATE/CLM
 L27 34083 SEA (CANCER OR TUMOR?)/CLM
 L28 13 SEA FRUCTOPYRANOSE SULFAMATE/CLM
 L29 727 SEA L24 OR L25
 L30 75 SEA L27 AND L29
 L31 66 SEA L26 AND L27
 L32 0 SEA L27 AND L28
 D L31 1-66
 D L31 AN TI PI KWIC 34 56 64 66

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter [HELP USAGETERMS](#) for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See [HELP SLIMITS](#) for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE MRCK

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005

THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.

FILE MEDLINE

FILE LAST UPDATED: 2 MAR 2006 (20060302/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Mar 2006 (20060302/PD)

FILE LAST UPDATED: 2 Mar 2006 (20060302/ED)

HIGHEST GRANTED PATENT NUMBER: US7007305

HIGHEST APPLICATION PUBLICATION NUMBER: US2006048257

CA INDEXING IS CURRENT THROUGH 28 Feb 2006 (20060228/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Mar 2006 (20060302/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 2 Mar 2006 (20060302/PD)

FILE LAST UPDATED: 2 Mar 2006 (20060302/ED)

HIGHEST GRANTED PATENT NUMBER: US2005259921

HIGHEST APPLICATION PUBLICATION NUMBER: US2006047476

CA INDEXING IS CURRENT THROUGH 28 Feb 2006 (20060228/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Mar 2006 (20060302/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=>